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Peritoneal infection that follows surgery is associated with SIRS and the development 
of multi-organ dysfunction.  It has a high mortality.  The dynamics of leucocyte 
trafficking into the peritoneal cavity and the expression of cytokines in response to 
either endotoxin or abdominal surgery will effect the development of both local and 
systemic inflammation.  Firstly the leucocyte trafficking in response to intra-
peritoneal LPS (lipopolysaccharide) is compared to an abdominal incision.  Then, 
using the expression of TNFα on the cell membrane as a marker of pro-inflammatory 
status, this expression is described in animals undergoing surgery followed by an 
‘second hit’ of ip LPS.  Finally the ability of these trafficked cells to trigger SIRS 
leading to pathophysiological effects in the lungs was assessed. 
Methods 
C57/B6 mice were exposed to either an intra-peritoneal dose of 20ng LPS or 
abdominal surgery and the leucocytes identified and counted in both blood and 
peritoneal lavage fluid by flow cytometry. A two-hit model was devised, abdominal 
surgery the primary hit and 24 hours later ip LPS the second hit. The expression of 
TNFα was measured with flow cytometry.  Using two intravenous dyes a lung 
permeability index was created comparing mice primed by surgery and those just 








The time course of migration was different for the various leucocyte sub-populations 
in response to both LPS and surgery.  There was a significant increase in the 
expression of membrane bound TNFα on monocytes and macrophages in the two-hit 
model than with surgery or LPS alone.  There was a trend to greater lung permeability 
in the two-hit group. 
Conclusions 
Leucocytes migrate to the peritoneal cavity after surgery and are primed to respond 
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Sepsis continues to be one of the commonest causes of mortality worldwide and is 
represented by a number of physiological changes that can take place in response to 
any infection.  At a molecular level the physiological changes are a result of 
identification of non-self (ie microbial cells) or damaged cells followed by activation 
of various cells of the immune system leading to an increase in production of 
cytokines, facilitating cell to cell communication.  This communication is a complex 
balance between pro- and anti-inflammatory cytokines, which in health regulate the 
appropriate response to infection but when this response becomes disproportionate the 
syndrome of sepsis occurs.  Surprisingly in many cases it is not the effects of the 
original infective insult but a dysregulated immunological response that leads to the 
majority of the cellular damage.  The picture is further complicated by the fact that it 
is not only sepsis that activates these cells and the cytokine cascade.  Sepsis is just one 
trigger for the systemic inflammatory response, it can also occur after tissue injury in 
surgery or trauma and non-infective inflammatory conditions such as pancreatitis.  
Infection and the sepsis that follows one of these inflammatory events can be 
devastating and has a high mortality. 
The innate immune system is the first part of the immune response and the 
mononuclear phagocyte system comprising monocytes and tissue resident 
macrophages play a central role within it as orchestrators of the overall response.  
Recently using new identification techniques several phenotypically and functionally 
distinct subsets of monocytes have been found in both humans and mice.  The cell 
surface expression of receptors aids identification of these cells and also gives some 
clues as to their role during inflammation.   
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This work tests the hypothesis that an abdominal surgical incision provides a stimulus 
for inflammatory cell accumulation within the peritoneal cavity and that these cells 
are primed to respond to any subsequent infection, producing effects that are distant 
from the origin of either surgery or infection, leading to multi-organ dysfunction. 
The current definitions and hypotheses of sepsis and systemic inflammation, the 
basics of innate immunity and the role of monocyte subsets in humans and mice are 
first reviewed. 
 
Sepsis, SIRS and surgery 
The definitions of the systemic inflammatory response syndrome (SIRS) and sepsis 
were developed at a consensus conference in North America in 1992 (1).  In fact it 
was at this conference that the term SIRS was first coined.  It had become obvious 
that unchecked inflammation could cause widespread organ dysfunction and that there 
were many diverse causative factors including trauma, cardiopulmonary bypass, 
surgery, pancreatitis and infection. 
In the years preceding this conference some researchers included all of these under 
the banner of sepsis whilst others had many variations within their inclusion criteria, 
not only was this confusing for clinical research it also made estimating the size of the 
epidemiological problem very difficult. 
From this conference the consensus was that a single common inflammatory pathway 
existed and should be termed SIRS.  Sepsis was re-defined as SIRS with a 
documented infective cause.   




(i) Heart rate >90 bpm 
(ii) Respiratory rate > 20 or a paCO2 < 32mmHg 
(iii) Temperature < 36°C or >38°C 
(iv) WCC < 4 or > 12 x109/L or more than 10% immature 
neutrophils 
 
There were also attempts to stratify the degree of insult with definitions for severe 
sepsis (sepsis with organ dysfunction), septic shock (hypotension that does not resolve 
with the administration of an appropriate amount of intravenous fluid) and multi-
organ dysfunction syndrome. 
These landmark definitions have been used for the last 20 years to improve the 
epidemiological assessments of sepsis and SIRS, to stratify patients into various sub-
groups allowing some individual risk assessments to be made and improve the 
recruitment of patients into trials aimed at the management of severe sepsis without 
including patients at lower risk of benefit but equal risk of harm. 
Although the ability to stratify patients has had some success and sepsis trials include 
more homogenous populations there are still many problems. Infection and sepsis 
appear to be an increasing problem within intensive care.  Mortality from sepsis is 
decreasing although the incidence continues to rise at a much more rapid rate, so the 
total number of deaths continues to rise. From 1979 to 2003 the mortality rate from 
sepsis decreased from 27.8% to 17.9% in the USA.  Over the same time period the 
incidence increased from 82.7 per 100,000 patients to 240.4 per 100,000(2).  If you 
just examine patients with severe sepsis there were over 750,000 cases with an 
associated mortality of 28.6%(3).  The incidence is increasing for many reasons; some 
related to the patients and some related to the infecting organisms.  People are living 
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longer, in part due to our ability to control chronic disease states, but they undergo 
more high risk debilitating surgery and many survive in relative states of 
immunosuppression.  Infectious organisms are also evolving rapidly, some would 
argue at a much fast pace than technology; multi-drug resistant bacteria are now 
commonplace both in hospital and the community and there are few new antibiotics in 
development. Over-use of antibiotics not just within medicine is a considerable 
problem leading to more and more resistance(2)(4).  In the worldwide point 
prevalence intensive care study, EPIC 2, infection was present in 51% of patients with 
75% of patients receiving antibiotics on the day of study. Mortality was significantly 
higher in the infected patients compared with those not infected (25.3% vs 18.2% 
p<0.001).  Multivariate logistical regression identified emergency surgery, age, 
cancer, heart failure, cirrhosis and immunosuppression as independent risk factors for 
death in the infected cohort(5).  
Surgery itself is a risk factor for SIRS but may also be the cornerstone of its 
management.  The injury induced by surgery shares many of the pathways activated 
in septic patients(6). The production of inflammatory cytokines such as IL-1β, IL-8, 
IL-10 and TNFα increases, with some evidence that the levels of these cytokines 
correlate with outcome in both sepsis(7) and wound healing(8).  Pattern recognition 
receptors (eg Toll-like receptors) identify both bacterial products(9) and intracellular 
proteins released from necrotic host cells(10) triggering the same intracellular cascade 
irrespective of the source.  Finally the response of the cells of the innate immune 
system including neutrophils and monocytes are similar regardless of whether the 
source of activation is sepsis or tissue damage(11).  
In a recent European study on surgical outcomes the overall crude mortality after 
surgery was 4.0% and a multivariate logistical regression identified emergency 
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surgery, age, cancer, heart failure and cirrhosis as independent risk factors(12).  It is 
perhaps not surprising given the common pathway of inflammation shared by surgical 
trauma and infection that the risk factors for death are almost identical in these two 
large observational studies (EPIC 2 and EUSOS).  The type of surgery also influences 
the risk, highest risks borne by vascular, upper gastrointestinal, lower gastrointestinal 
and hepato-biliary surgery(12).  The size of incision, tissue trauma involved and risk 
of infection from intra-luminal contents make abdominal surgery particularly risky.  
Within the peritoneal cavity, surgery is often the mainstay of treatment for infection 
leading to peritonitis but infection may also follow and complicate routine or 
emergency abdominal surgery.  There is likely to be complex interplay between the 
inflammatory effects of the surgery itself and the septic process. This may be why 
patients who develop peritonitis have a significant degree of mortality and morbidity. 
In EPIC 2, 20% of the documented infections were intra-abdominal(5) and Marshall 
previously found that the mortality of intra-abdominal infection was 30%(13).If the 
infection follows surgery and is persistent then mortality can rise to between 30 and 
64%(14)(15).  This is tertiary peritonitis. 
Primary peritonitis is a spontaneously occurring event in patients with ascites and may 
have its origin in the translocation of bacteria across the gut wall.  Secondary 
peritonitis is associated with perforation of a hollow viscus, as occurs with 
diverticulitis or a duodenal ulcer; it is a common diagnosis managed by acute 
surgeons.  Those patients who succumb at an early stage from secondary peritonitis 
do so because of overwhelming breach of the gastrointestinal tract and massive 
release of bacterial products and toxins.  Those who survive the early stages, usually 
with prompt surgical intervention and early use of antibiotics, either recover or 
develop a chronic inflammatory condition.  The latter is associated with SIRS, multi-
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organ failure and a higher mortality and is known as tertiary peritonitis(14).  There are 
patients who respond much better to treatment despite a similar insult and this 
heterogeneity is likely to be a function of both genetic polymorphisms(16), the so 
called “survivor genes” and the number and severity of co-morbid conditions.  
 
Surgical management of intra-abdominal sepsis 
The traditional mainstay of treatment for many of the causes of peritonitis is source 
control, commonly involving surgery.  However recently there has been an 
acceptance that there are significant risks associated with surgery and the benefits that 
initially appeared intuitive may be less so.  A good example of this is the management 
of appendicitis.  Ten years ago this was managed in the vast majority of patients with 
open surgery.  More recently laparoscopic surgery has become the standard of care in 
many centres due to lower morbidity, lower complication rate and lower hospital 
length of stay using this approach(17).  In fact since the 1970’s there has been a 
growing amount of evidence that not all patients with suspected appendicitis need 
surgery at all and many can be managed with a course of antibiotics(18)(19)(20).  The 
key to this is patient selection, and the ability to make the right choice for individual 
patients has significantly improved over the last 30 years using imaging modalities 
such as ultrasound and computer tomography.  This more conservative approach to 
the management of not just appendicitis but other causes of intra-abdominal sepsis has 






Supportive management of intra-abdominal sepsis 
In those patients who require abdominal surgery the role of Intensive Care has grown 
over the last decade.  In the UK there have been attempts to stratify patients in whom 
higher nursing ratio’s, intensive monitoring, close attention to fluid balance and 
antibiotic husbandry would reduce significant morbidity and mortality.  There is a 
growing amount of evidence that higher levels of care can reduce complications 
following high risk surgery(21)(22). 
The improvements in mortality that have been made over the last 30 years have 
occurred not because of a specific targeted therapy but by improvements in the quality 
of supportive care offered within Intensive Care units.  In fact one could argue that we 
are just causing less harm in our efforts to cure.  This includes interventions such as 
low tidal volume ventilation(23), high PEEP(24), prone positioning(25), goal directed 
therapy(26), resuscitation fluid selection(27)(28) and volumes(29) as well as many 
more.  Along the way we have stopped or adapted interventions that have been found 
to be ineffective or harmful such as tight glycaemic control(30)(31), albumin for fluid 
resuscitation(32) and high frequency oscillation(33)(34). 
 
The innate immune system and potential therapeutic targets in sepsis 
The innate immune system was thought of as a blunt tool in the immunological 
response that responded in a very non-specific way to a variety of insults.  However in 
the last 20 years there have been numerous advances in our understanding of this 
system including the discovery of a superfamily of receptors identifying both 
microbial products and damged host cells (35), the links between the innate and the 
adaptive systems (36) and the biology of cell surface markers allowing the 
identification of subtle subsets of the cells involved.  
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There are several different facets to the innate immune system.   It must be able to 
recognise invading organisms and the toxins they produce as well as discriminate 
between damaged and healthy cells.  On recognition, the cellular components of the 
system must translate this message into the nucleus, increasing DNA transcription to 
produce substances that will eradicate the identified problem. These sensing and 
effector functions must also have the ability to turn off when the problem is 
controlled. This system is very sensitive and effective, persistent infections are rare 
but there are many instances where the response to infection not only eradicates the 
invading organism but also causes significant damage to the host (37). 
 
Ligands - PAMP’s and DAMP’s 
The recognition of pathogens is primarily cell-based.  Receptors on the cell surface 
are able to recognise pathogen associated molecular patterns (PAMPs) and/or damage 
associated molecular patterns (DAMPs)(38).  PAMP’s can take many different forms 
including dsDNA from viral organisms, peptidoglycan and lipoteichoic acid from 
Gram positive bacteria and endotoxin from Gram-negative bacteria.  In the 1800’s 
Pfeiffer named the latter with the discovery that a constituent of bacteria was able to 
kill experimental animals even if the bacteria itself had been rendered non-viable; he 
named this endotoxin (39).  This has been found to be the most potent of the several 
bacterial components that can trigger inflammation and this has pushed researchers to 
try and block its effects prior to the interaction with cells of the innate immune 
system.  An anti-endotoxin monoclonal antibody called centoxin did show 
effectiveness in animal models and a phase 2 trial.  However the first large 
randomized trial did not show benefit, except in the sub-group with confirmed gram 
negative sepsis (40).  Further larger trials with a-priori defined subgroups failed to 
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find any mortality advantage and finally a large French study not only demonstrated 
no benefit but a signal towards harm, the product was rapidly withdrawn (41). 
Damage associated molecular patterns (DAMP’s) are endogenous ligands that can be 
recognised by pattern recognition receptors on cells of the innate immune system.  
They are released following cell damage or necrosis. 
There are many of these that have been identified including High mobility group box 
protein (HMGB), heat shock proteins, S100 proteins, RAGE, formyl peptides, ATP 
and nuclear factors (42).   
HMGB has probably been the most studied, it is a component of the nucleus of cells 
and is released by cells undergoing necrosis.  It is also released by macrophages and 
monocytes, without cell death, as a signal to recruit more inflammatory cells to areas 
of damage (10).  It is identified by TLR-4 in a very similar way to the identification of 
LPS and the downstream activation effects in monocytes may be similar(43).    
Pattern recognition receptors are able to identify both PAMPS and DAMPs and 
although there is some small differences in the downstream effects, most are 
conserved regardless of the stimulus.  The initial identification is usually made by 
either sentinel macrophages or patrolling monocytes(44)(45) and these respond by 
sending out a chemokine signal to attract neutrophils.  Neutrophils contain numerous 
granules, the first released aid their migration to areas of inflammation, subsequently 
released chemicals aid the clearance of microbes/damaged cells.  Neutrophils also 
alter the chemokine gradients and signal to endothelial cells to driving the attraction 
of monocytes (46)(47).  In an animal model of sepsis where neutrophils were depleted 
the numbers of monocytes recruited to areas of infection were significantly reduced 
(48).  Finally to limit the degree of inflammation, macrophages prevent further 
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neutrophil sequestration, send signals to actiavte neutrophil apopotosis and then 
scavenge the remaining cell debris (49). 
The immune system was traditionally viewed as differentiating between self and non-
self but perhaps should be considered as a response to triggers that may cause harm be 
they self or non-self. 
 
Receptors  
Following the identification of the ligands that activate the innate immune system the 
obvious next step was to search for the receptors.  It had been noticed that a strain of 
mice (C3H/HEJ) was resistant to the effect of injected endotoxin, suggesting that a 
single receptor existed (50).  It was only later that the mutation in these animals was 
found to code for part of the cytoplasmic domain of a transmembrane receptor called 
Toll-like receptor 4 (51).  The Toll-like receptors were first discovered in the fruit fly, 
Drosophilia Melangastor (35) and they are remarkably conserved across many 
species.  Their role as receptors was established in the 1990’s (52) but their full 
function is only just beginning to be understood.  In humans there are several Toll-
like receptors that are configured either to identify single ligands or in some cases 
multiple consitituents of the invader.  TLR-1,-2 and -6 recognise several bacterial 
lipoproteins, TLR-4 recognises LPS, TLR-5 responds to flagellin - an intracellular 
component of bacteria and TLR-3, -7, -8, -9 all recognise demethylated nucleic acids 
and are thus able to differentiate between DNA/RNA from bacterial or viral 
organisms and mammals (53).   
TLR-4 typifies the toll-like receptors.  It is a transmembrane protein with a 
extracellular portion that forms a hydrophobic pocket to bind LPS. When released 
from bacterial cell walls, LPS rapidly forms micelles in solution and so, to aid its 
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presentaton to TLR-4, it first binds to Lipopolysaccharide binding protein (LBP) 
(54)(54) and a co-receptor CD14 (55) found either on monocytes or in a free soluble 
form.  These facilitate the delivery of single molecules of LPS to TLR-4 and promote 
binding.  Once LPS is bound the intracellular portion of the Toll-like receptor is 
activated. This involves a Toll/IL-1 receptor (TIR) domain interacting with several 
bridging adaptors such as MyD88 and activating downstream proteins such as the 
Interleukin receptor associated kinase (IRAK) family (53).  One of the common 
targets of this intracellular signalling process is to activate Nf-κB, promoting its 
translocation into the nucleus and the transcription of pro-inflammatory cytokines 
such as Tumour Necrosis Factor (TNFα) and IL-6.   
In humans TLR-4 receptor polymorphisms are known but often make the individual 
more susceptible to sepsis rather than less.  This may be in part due to the presence of 
multiple pathways for the detection of microbial DNA, debris and endotoxin that 
include but are not limited to the TLR system such as fmLP and the intracellular 
sensors NOD1 and NOD2. 
Downstream effects 
TNFα is part of a genetic superfamily that has evolved with a wide range of diverse 
functions including organogenesis, apopotosis, inflammation and host defense (56). 
There are two receptors found on cell membranes for TNFα, the 55kD TNFR-1 and 
the 75kD TNFR-2.  Evidence is beginning to emerge that these two receptors may 
have opposite downstream effects which may explain why non-specific TNFα 
anatagonists have proven ineffective to manage sepsis (57).  The control of TNFα is 
complex and involves a membrane bound enzyme TNFα converting enzyme (TACE) 
also known as CD156b. This is an ADAM-17 metalloprotease and is involved in the 
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cleavage of more than 40 proteins from the cell surface including both TNFα and 
TNFR. TNFα is synthesised and transported to the cell surface as a 26kD membrane 
bound precursor, this is subsequenty cleaved to form the 17kD soluble form by TACE 
(58). By cleaving both TNFα and its receptor TNFR from the cell membrane, it can 
regulate both the pro- and anti-inflammatory properties of TNFα (59).  One example 
of this is the ability to dampen down the response to infection by binding soluble 
TNFα to free TNFR, therefore neutralising it. The effects of TNFα binding to  
membrane bound TNFR are many and diverse.  In the context of sepsis they promote 
programmed cell death in some target cells yet, delay apoptosis in others (56)(60).  
They also have a chemokine function and co-ordinate the recruitment and activation 
of a variety of cells to the areas of infection maximising the response (56).  Animals 
infused with a recombinant form of TNFα exhibit many of the signs of sepsis 
including hypotension, metabolic acidosis, endothelial leak and hyperglcaemia.  On 
post mortem examination of the lungs there are the characteristic changes of 
pulmonary oedema and inflammatory cell infiltration. Taken together this suggests a 
central role for TNFα in the pathophysiology of sepsis(61).  In animal models the 
levels of TNFα correlate well with the degree of insult and mortality(62) and there is 
some evidence that this is also true in children with meningococcal disease(63).  
However there is little correlation in many of the other causes of sepsis, in fact in 
many studies on septic patients researchers failed to detect TNFα at all(64). 
Given it’s central role a substantial amount of time and money has been invested in 
trying to find an anti-TNFα drug that is effective in sepsis.  A product was developed 
and studied in a multi-centered, randomized, double blind, placebo controlled trial. 
Unfortunately although there was a mortality benefit at 3 days this was lost by 28 
days, the a priori primary outcome measure(65). In 2001 another multi-centre 
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randomized controlled trial was published, this time the intervention group receiving 
the p55 soluble TNFα receptor, with the aim of binding free TNFα in plasma 
preventing its effects(66).  There was strong animal data for a significant mortality 
benefit and a phase II study that suggested if used early then mortality was reduced at 
28 days(67).  Unfortunately once fully randomized and properly powered to examine 
mortality as an end point there was no statistical difference between the p55 TNFα 
receptor and placebo(66). 
The downstream response does not just involve TNFα; there are many cytokines that 
have effects in inflammation.  The system is highly complex and each cytokine may 
have a role in both the pro- and anti-inflammatory response, one explanation of this is 
the competition between cytokine cell surface receptors and circulating forms. This is 
well illustrated by IL-6.  It is probably the most studied pro-inflammatory cytokine 
and many researchers have demonstrated its increase in sepsis, during surgery and 
following trauma (68). There is an asoociation between high levels of IL-6 and 
mortality in sepsis (69).  However it also has some anti-inflammatory properties and 
given the right conditions it downregulates the production of IL-1 and TNFα without 
effecting the production of other anti-inflammatory cytokines such as IL-10 (70).   
IL-10 is commonly studied as an anti-inflammatory cytokine and is able to reduce the 
production of inflammatory cytokines such as TNFα and IL-6 in all myeloid cells 
both at a translational and post-translational level (71).  In patients with an infective 
exacerbation of COPD there is a clear timeline of cytokine release, TNFα appears 
early and is followed by IL-6 and then IL-10 much later on (72).   
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Coagulation and sepsis 
More recently the connection between coagulation and sepsis has been identified as a 
possible area for therapeutic intervention.   During sepsis there is an imbalance 
between pro- and anti- coagulant factors, with a decrease in the synthesis of protein C, 
protein S and anti-thrombin III as well as thrombomodulin, the latter a molecule 
required for protein C activation. Activated protein C has an important role in turning 
off the coagulation cascade by decreasing plasminogen activator inhibitor 1 (PAI-1) 
and inhibiting factor Va and VIIIa; it also has a role in decreasing apoptosis.  By 
inhibiting both the synthesis and activation of protein C, endotoxin both increases 
fibrin whilst inhibiting fibrinolysis.  This creates microvascular thrombi, areas of 
ischaemia and further cell damage (73).  This was the premise for the 2001 
PROWESS trial that compared recombinant activated protein C with placebo (74).  
This trial demonstrated a very impressive 6% absolute risk reduction in the primary 
outcome of 28-day mortality; however later studies failed to find benefit and there 
was a suggestion of excess mortality from bleeding complications.  This led to an 
unprecedented second randomized controlled trial in 2011, PROWESS-shock.   The 
drug was trialed in units with little prior use to ensure equipoise and after recruiting 
1697 patients, all with septic shock they found there was no statistical mortality 
benefit of activated protein C at 28 days (75).  The pharmaceutical company Eli Lilly 





SIRS vs CARS 
In 1972 Lewis Thomas proposed that bacteria were simply “bystanders” in sepsis and 
the real enemy was an overactive immune response (76).  The obvious extension to 
this is that by preventing over-activity, mortality should reduce.  Many different 
targets and potential therapies have been tried in the last 30 years with very little if 
any success, and this has led to questions about whether this original hypothesis was 
true.   
Bone introduced the term compensatory anti-inflammatory response syndrome 
(CARS) to explain why many sepsis patients do not succumb to the original infection 
but at day 3 or 4 often from a secondary insult (77).  Hotchkiss and Karl in their 2003 
review suggest that there is a fine balance between pro- and anti- inflammatory 
responses and the same cell types or cytokines in different situations may produce 
both types of effect (16). One hypothesis is that there is over-stimulation of the anti-
inflammatory compensatory response leading to a state of relative immunoparalysis.  
This could help explain why many of the intervention trials for sepsis have failed to 
show any mortality benefit.  What remains controversial is the timeline of events; 
does either SIRS or CARS dominant, do these processes occur sequentially or is 
CARS simply the normal process of turning off of inflammation.   These questions 
have clear therapeutic implications; improvements in organ support have decreased 
early death from sepsis but the development of immunomodulatory drugs continues to 
be directed towards reducing activation of the pro-inflammatory arm.  Many authors 
believe that future developments need to be targeted to an individual’s immune status 
using genetic profiling.  
The compensatory response is complex and includes both cellular and soluble 
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mediators.  Monocytes from septic patients exposed to LPS, produce less TNFα, IL-
1α, IL-1β, IL-6 and IL-12 but significantly more IL-10 (78).  This also seems to be 
the case following trauma (79).  It has also been known for several decades that serum 
taken from either burns (80) or septic patients (81) is able to blunt the pro-
inflammatory response of leucocytes from healthy volunteers.  These circulating 
factors include soluble CD14 and LPS binding protein, that act by “mopping up” 
circulating LPS.  Soluble TNFα receptors perform a similar role with TNFα (78). 
To demonstrate these effects in patients Hotchkiss compared lung and splenic tissue 
from patients who died of sepsis with that from alive trauma patients including those 
who were brainstem dead (82).  Splenic cells from patients who died from sepsis 
produced less cytokines than control patients.  This was true for both the pro- and 
anti-inflammatory cytokines including TNFα, IFNγ, IL-6 and IL-10.  At a molecular 
level antigen presenting cells express less HLA-DR and more of the programmed cell 
death family in the septic patients.  This provides some support for the theory of a 
general decrease in immunity related to a change in innate immune cells surface 
expression and an increase in apoptosis.  Clinically an alteration in the ratio of pro- 
and anti-inflammatory cytokines can have an effect on outcome.   In meningococcal 
disease, mortality is higher in patients and their 1st degree relatives who have either a 
raised IL-10:TNFα ratio (83) or a raised TNFα to soluble TNFα receptor ratio (84). 
In summary the effects of CARS may manifest in several ways.  It may simply be 
over-production; persistently raised IL-10 levels in sepsis confer a worse 
outcome(85). It may be that a cytokine signal triggers apoptosis and increased cell 
death; with a knock on effect on immune cells leading to anergy, or a state of 
unresponsiveness(86). It may be that the cells of organs with significant dysfunction 
 25 
simply hibernate and could be available to function normally given the right 
metabolic conditions.  Autopsy evidence suggests that there is actually very little cell 
death in sepsis, a finding that seems at odds with the degree of macro organ 
dysfunction.  It is likely to be a combination of several diverse mechanisms. 
Innate Immune system 
The complexity and redunancy within the system with several different pathways 
leading to the same end-point is both a strength and a weakness.  It gives the immune 
system the flexibility to react to many different pathogens but when imbalance 
between the pro- and anti inflammatory responses occurs, blocking one facet of the 
pathway is unlikely to fix the problem and may conversely lead to harm.  The “magic 
bullet” probably does not exist for the management of SIRS or sepsis due to 
significant interpatient heterogenity but for some disease states modicfication  of this 
innate immune response has been effective.  These include Rheumatoid arthritis (87) 
and hepatitis B (88).  It is interesting that although beneficial at reducing the impact of 
the underlying disease these modifications are often accompanied by a predisposition 
to sepsis (89). 
Neutrophils 
The leuckocyte subpopulations involved in the innate immune system arise from 
common progenitor cells within bone marrow.  They employ a range of killing 
strategies to remove invaders from the host.  The polymorphic neutrophils (PMN’s) 
have a short half live, in resting conditions most will undergo apopotosis in around 6 
hours.  Interestingly apoptosis in neutrophils can be delayed by high circulating levels 
of TNFα to facilitate bacterial clearance (60). In response to infection there is a rapid 
mobilisation of PMN’s from bone marrow and following cytokine and chemokine 
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gradients they migrate to the infected areas. Phagocytosis occurs either via receptors 
on the cell surface or complement enhanced opsonization, followed by the release 
from lysozomes of several intracellular compounds including reactive oxygen species, 
hydrogen peroxide and peroxynitrite (37).  Once phagocytosis has occurred there is an 
immediate signal to begin apoptosis allowing control of this powerful immune 
response.  More recently the concept of neutrophil extracellular traps (NETs) has been 
developed as another putative mechanism by which neutrophils eliminate bacteria and 
cell debris (90).  NETs are formed by the ejection of nuclear material including 
histones from the cell a process that may or may not lead to neutrophil cell death.  
This occurs in response to either whole bacteria or component parts from a wide range 
of organisms.  They trap bacteria in the peripheral circulation, limiting spread as well 
as being bacteriocidal.  Abnormal NET release has been implicated in the aetiology of 
chronic infective conditions and some autoimmune diseases including vasculitis (91) 
and SLE (92). 
Macrophages 
Macrophages are mostly tissue based and have a much longer half life than other cells 
of the innate immune system (37).  They are replenished by circulating monocytes 
that are not just delivery cells but biologically active with diverse roles depending on 
the subset.  The killing mechanisms are very similar to neutrophils, although the 
target and time course often differ.  Tissue macrophages act as sentinel cells that are 
the first part of the innate immune system to detect either PAMP’s or DAMP’s, 
triggering an increase in production of inflammatory mediators such as TNFα and IL-
6 (93).  Chemokine gradients then develop to attract neutrophils and monocytes to 
these areas of inflammation. The same cells also help in the repair of damaged tisue as 
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inflammation subsides.  The act of phagocytosis of apoptic cells increases the 
production of anti-inflammatory cytokines such as TGFβ and a variety of growth 
factors whilst decreasing the production of pro-inflammatory cytokines (94).  
Specialised macrophages in the liver (Kupffer cells) and spleen are involved in 
clearance of systemic pathogens by phagocytosis.  They are also implicated in some 
chronic disease states such as alcohol induced cirrhosis (95). 
 
Monocytes 
Initially, monocytes were thought of as cells that only became activated when they 
had marginalised out of the circulation and differentiated into macrophages (96)(45).  
However recently it has become apparent that there are subsets of monocytes with 
very different roles in the sepsis response and these can be clearly documented in 
many different species (97). Rather than a passive, reactive role they may actually 
orchestrate some of this intertwined complex process. These subsets have been 
demonstrated in both mice and humans and although some similarity exists the 
functional characteristics are not identical between species. 
 
Human Subsets 
Several groups had identified different subsets of human monocytes on the basis of 
countercurrent centrifugal elutration (98)  (99) but it wasn’t until Passlick et al 
described a novel combination of surface antibodies by flow cytometry that the 
current method of a characterization of the subsets could be achieved (100).   Using 
two colour flow cytometry and cell sorting they identified two subsets of monocytes 
in volunteers blood.  The larger, more granular cells make up 90-95% of the 
monocyte numbers and express mostly CD14; they were termed classical monocytes.  
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The smaller cells representing 5-10% of the total monocyte count express both CD14 
and CD16.  The functional characteristics of both of these subsets remain 
controversial.  As already discussed, CD14 is a cell surface receptor acting as a co-
receptor with soluble LBP to present LPS to TLR-4.  CD16 or FcγIIIR is a cell 
surface receptor for the Fc portion of IgG.  The initial characterization suggested that 
the CD14+/CD16+ cells were more efficient at antigen presentation but produced less 
TNF, IL-6 and IL-10 than the CD14++/CD16- cells (101).  In later experiments the 
same group failed to reproduce their findings; by measuring mRNA instead of soluble 
cytokines an equal amount of TNF, IL-1 and IL-6 was produced by the two subsets 
but the CD14++/CD16- cells produced significantly more IL-10 (102).  By using whole 
blood and flow cytometric analysis of intracellular TNF, they found a significantly 
greater production of TNF by the CD14+/CD16+ cells; this was especially marked 
following stimulation by the products of Gram Positive bacteria (103).  These two 
studies led to the CD14+/CD16+ cells being labeled as pro-inflammatory.  As flow 
cytometric technology improved, the surface expression of proteins on the subsets has 
been studied in much greater detail and become more complex.  Grage-Griebenow et 
al defined monocytes using CD14, CD64 (a high affinity receptor for IgG) and CD16, 
identifying three populations.  CD64+/CD14+/CD16- analogous to CD14++/CD16-, 
CD64-/CD14dim/CD16+ analogous to CD14+/CD16+ and a third, novel group 
CD64+/CD14+/CD16+ (104) (105). As well as differences in cytokine/chemokine 
production the subsets also differ in the mechanisms they employ to migrate into 
areas of inflammation.  The CD14++/CD16- subset express similar amounts of TLR-4 
but significantly more TLR-2 (103) (106). They migrate into tissue via CCR2 and 
MCP-1 dependent mechanisms and are able to either produce myeloperoxidase and 
reactive oxygen species (ROS) or differentiate into macrophages (107). The 
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CD64+/CD14+/CD16+ subset have previously been included with all the CD16+ cells, 
they express both TLR-2 and TLR-4 and have the typical morphological appearance 
of a monocyte. However they have a high expression of HLA-DR and CD11c, greater 
T cell accessory capacity and a high production of IL-12, all traits of dendritic cells 
(DC’s) and they may represent an intermediate form of either dendritic cell or 
CD14dim/CD16+ monocytes (104).  The CD14dim/CD16+ subset expresses both TLR-4 
and TLR-2 and are probably the most mature cell line with in vitro evidence of 
maturation from the CD14++ cells via the intermediate CD64+/CD14+/CD16+ form 
(106) (108).  Both subsets expressing CD16 also express CX3CR1 the receptor for 
fractalkine and CCR5 the receptor for macrophage inflammatory protein-1 (MIP-1) 
providing an alternative mechanism for adherence and migration. 
Subsequently, there have been numerous observational studies examining the 
trafficking and in-vitro activity of the different subsets in both healthy volunteers and 
patients (109). It appears that the minority subset, CD14+/CD16+ increases 
dramatically in several clinical situations including active rheumatoid arthritis (110) 
neonatal sepsis (111), gram negative sepsis, erysipelas (112), HIV (113), lupus (114) 
and even with strenuous exercise (115).  More recently a biphasic kinetic for the 
migration of monocytes into myocardium following myocardial infarction has been 
described (116).  The experimental work in humans does need to be interpreted with 
caution, many of the methods involved in the earlier separations of subsets may have 
activated the cells and subsequent increases in cytokines may just represent in-vitro 
phenomena.  This is a common criticism of all in-vitro work and has pushed 
investigators to find monocyte subsets in suitable laboratory animal models that will 
allow the study of in-vivo responses (117). 
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Murine subsets - heterogeneity 
In 2001 during a study investigating the effect of the chemokine, monocyte 
chemoattractant protein 1(MCP-1/CCL2) Palframan et al discovered that there 
appeared to be at least two monocyte subsets in mice and they could be separated by 
their expression of CCR2, CX3CR1 or L-selectin (118).  There was also a suggestion 
that these different subsets also had different functions with only the CCR2+ cells 
migrating to inflamed peripheral lymph nodes (119). Geissman et al expanded this 
significantly in 2003 using Rag deficient mice to increase the yield of monocytes and, 
like Palframan, used animals where a single allele of the gene coding for CX3CR1 
was replaced by green fluorescent protein (GFP) (120). They identified 2 subsets; 
CX3CR1Lo expressing high levels of CCR2, the Ly6C/G complex Gr-1 and CD62L 
(L-selectin); the other subset was CX3CR1Hi, low expression of the Gr-1 complex and 
minimal CCR2 or CD62L.  Several groups have confirmed these results and murine 
monocytes are now clearly divided into 2 distinct subsets known as Gr-1Hi and Gr-1Lo 
(45).  
In the same paper, Geissman examined the effect of inflammation using adoptive 
transfer of GFP labeled monocytes into the circulation of donor mice, which had 
previously had sterile peritonitis, induced with thioglycollate. In normal wild type 
recipient mice the Gr-1Lo monocytes circulated for several days migrating into normal 
tissue such as liver, lung and spleen, whereas the Gr-1Hi cells rapidly became 
undetectable in all tissues. In peritonitic mice the Gr-1Hi monocytes migrated within 
18 hours to the site of inflammation whereas the Gr-1Lo cells mostly remained in the 
circulation and extravasated in much lower numbers.  Gr-1Hi monocytes were also the 
first cells to migrate in response to sterile peritoneal inflammation with an attractant 
signal from tissue expressed MCP-1 (119).  
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They hypothesised that the Gr-1Hi cells migrated in response to inflammation whereas 
the Gr-1Lo cells had a more patrolling role, maintaining normal tissue homeostasis. 
This was reinforced by the work of Auffray, who, using confocal intravital 
microscopy, demonstrated Gr-1Lo monocytes crawling along the luminal border of 
endothelium (121).  The process of rolling along endothelium in areas of 
inflammation is well known and allows the interaction of endothelial chemokine’s 
with their cell surface receptors as well as encouraging extravasation at tight junctions 
(122).  The pattern of movement of the Gr-1Lo monocytes was different; it was present 
predominantly in healthy tissue and occurred both with and against the flow of blood 
and for a much further distance than the rolling of other leucocytes.  The appearance 
was that of a ‘patrolling’ cell. Using antibodies against the integrin LFA-1 this 
attachment to the endothelial luminal border was disrupted, and CX3CR1 deficient 
mice had a significant reduction in both the number of patrolling cells and the 
distance they moved (121). This suggests a role for both of these cell surface proteins 
in this patrolling behavior.  Experimental proof of the function of these patrolling Gr-
1Lo monocytes is lacking although the hypothesis that they phagocytose dead cells and 
circulating oxidized lipids during health is credible.  The natural ligand for CX3CR1 
is fractalkine and this interaction is likely to mediate the patrolling role, the union of 
these proteins also appears to send a survival signal to the monocyte significantly 
prolonging its lifespan although the mechanism for this is currently unknown. 
(121)(45,123).  Interestingly CX3CR1 although minimally expressed also has some 
role on the Gr-1Hi cells. In CX3CR1 deficient mice that have been infected with 
Listeria, bacterial cell numbers are less well controlled by Gr-1Hi cells and they 
migrate to the spleen in much fewer number (124). 
Intra-peritoneal injections of Listeria demonstrated that these patrolling cells 
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extravasated to areas of infection within 2 hours and rapidly became the prime 
producers of TNF and IL-1.  The more traditional ‘inflammatory’ monocytes, Gr-1Hi 
did not migrate to the peritoneum for up to 8 hours at which point they took over the 
role of inflammatory cytokine producer (121).  By this stage the Gr-1Lo monocytes 
had already changed to a more reparative role, switching to the production of mRNA 
coding for proteins involved in tissue remodeling (125).  The end result is that the two 
monocyte subsets differentiate differently following the same stimulus, Gr-1Lo cells 
mature into cells that resemble alternatively activated M2 macrophages and Gr-1Hi 
cells have some of the features of pro-inflammatory circulating dendritic cells (121).  
There is evidence from other experimental models that this is indeed the case with the 
same stimulus causing the different subsets to mature into distinct cell types with 
distinct functions.  Hypercholesterolaemia in mice triggers several responses 
including an increase in the numbers of Gr-1Hi monocytes.  These migrate into 
atheromatous areas and drive the inflammatory response within these plaques; they 
may also eventually differentiate into foam cells. Gr-1Lo cells have a less defined role 
in atherosclerosis but they may have a stabilizing effect on plaques by differentiating 
into M2 macrophages and forming granulation tissue (126).  Nahrendorf et al 
summarized the work done on monocyte subsets following a myocardial infarction as 
a bi-phasic response; an initial influx of pro-inflammatory Gr-1Hi monocytes migrate 
using a CCR2 dependent pathway and are involved in the clearance of free lipids and 
dead myocytes.  This is followed by migration of Gr-1Lo cells, utilizing CX3CR1, and 
leading to granulation, fibrosis and repair (127)(128).  In muscle injury again it is the 
Gr-1Hi monocytes that are recruited in the first 48hrs of necrosis producing significant 
amounts of IL-1β and TNFα. By day 4 the predominant cell type is Gr-1Lo expressing 
more TGFβ and IL-10, and by day 10 when nucleated cells are beginning to reappear 
 33 
few monocytes remain (129).  In this model the Gr-1Lo cells appear to be derived from 
the Gr-1Hi cells, the signal triggering this switch may be the phagocytosis of dead 
cells.  In mice depleted of monocytes around the time of injury very little 
phagocytosis or regeneration occurred. 
Finally in acute lung injury there is clear evidence for a differential role of monocyte 
subsets. O’Dea et al demonstrated that there was a significant increase in the pro-
inflammatory cytokine production, specifically TNFα, of monocytes that had 
marginated into the pulmonary vasculature and out of the central circulation, in 
response to an intra-venous injection of LPS (130).  The lung has a unique response to 
systemic challenges as most leucocytes have to deform to pass through the narrow 
capillary beds (a process hampered by the action of LPS) and almost the entire cardiac 
output must pass through the lung vasculature (131).  O’Dea et al demonstrated that 
Gr-1Hi monocytes are mobilised from bone marrow and marginate within the 
pulmonary vasculature in response to a sub-clinical dose of IV LPS (132).  These 
cells produce little membrane bound TNFα but have clearly formed a degree of cell-
cell interaction because following a secondary stimulus of clinical significant LPS 
there was a 5 fold increase in the amount of membrane TNF expressed compared to 
non-primed monocytes.  Using targeted inhibition of the monocytes response with 
clodronate-liposomes it was apparent that these effects were in the main mediated by 
the Gr-1Hi subset rather than Gr-1Lo monocyte or other leucocytes. Wilson 
demonstrated a similar effect to O’Dea using high stretch ventilation instead of a 
second dose of LPS (133).  Mice pre-treated with a sub-clinical dose of LPS were 
liable to greater lung injury when subsequently exposed to high stretch ventilation.  
This injury could be attenuated using clodronate to deplete the circulating monocytes.  
The predominant subset recruited was Gr-1Hi.  This heterogeneity between the subsets 
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is determined by the phosphorolyation of p38 and activation of its substrate 
MAPkinase (Mitogen activated Protein) specifically MK2. TNFα production is 
consistently higher in the Gr-1Hi monocytes and associated with higher levels of 
Phospho p38 and activated MK2.  This production of TNFα can be reduced to 
baseline levels with the addition of MAPkinase inhibitors suggesting a significant role 
in the production of cytokines (134).  The experiments of Wilson also combines tissue 
damage and infection to examine the effect of the two hit insult. 
 
Murine subsets - trafficking 
Monocytes arise from bone marrow, specifically from progenitor cells called 
macrophage/dendritic precursors (MDP).  These are the parent cells for both subsets 
of monocytes, conventional dendritic cells, plasmacytoid dendritic cells and 
macrophages.  There appears to be a role for both CX3CR1 and the M-CSF receptor 
(CD115) during development as the former is first expressed on the MDP cells and 
the latter on the more pluripotent granulocyte/macrophage progenitors.   
The expression of Gr-1Hi on monocytes appears to peak just before release from bone 
marrow.  These cells then appear to preferentially migrate into areas of either sterile 
inflammation (135) or infection (120).  By selectively removing monocytes from the 
central circulation using liposomal clodronate and then sequentially examining their 
re-population it is possible to examine the maturation of the monocyte response.  
Following an intravenous injection of clodronate most monocytes have been removed 
from the central circulation by 18hours. At 48 hours re-population has begun almost 
universally with bone marrow derived Gr-1Hi cells which, as they mature, express Gr-
1 less and less resulting in the Gr-1Lo subset.  Labeling the initial Gr-1Hi cells with Dil 
and following their maturation confirms the development of Gr-1Lo cells from the Gr-
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1Hi.  In times of inflammation the expression of Gr-1 actually increases representing a 
left ward shift to a more immature cell released from bone marrow, similar to the 
leftward shift of neutrophils (135). 
This builds a picture of Gr-1Hi cells released from bone marrow under the influence of 
CCR2, in times of no inflammatory stimulation there is a no activation of CX3CR1 
and these cells either undergo apoptosis or differentiate into the more mature Gr-1Lo 
cells.  In times of inflammation these Gr-1Hi cells rapidly migrate to areas producing 
significant amounts of MCP-1 such as resident macrophages or the mesothelial cells 
lining the peritoneum (119).  The Gr-1Lo cells, which routinely patrol the 
endothelium, are immediately available to rapidly migrate into areas of inflammation 
and assist in this recruitment. 
There are several similarities between the murine and human monocyte subsets.  The 
Gr-1Hi and CD14+/CD16- cells are larger than Gr-1Lo and CD14dim/CD16+ cells and 
express a similar variety of surface molecules.  Gr-1Hi and CD14+/CD16- monocytes 
both express CCR2 whereas Gr-1Lo and CD14dim/CD16+ cells express CX3CR1.  
There are, however, some differences in subset function between species that appear 
contrary to this homology.  In mice the main producer of TNFα is the Gr-1Hi 
monocyte, whilst the Gr-1Lo subset patrol blood vessels (45) and may have a 
reparative role in tissue injury (127).  In humans however the CD14+/CD16- cells 
have a more anti-inflammatory role with increased production of IL-10, whilst the 
CD14dim/CD16+ cells produce the majority of TNFα(136).  Recent microarray 
genomic sequencing has discovered that the CD14+ cells including CD14+/CD16- and 
CD14+/CD16+ map a similar cluster of genes as the Gr-1Hi murine cells (137).  The 
expression of TNFα is actually highest on the intermediate CD14+/CD16+ cells when 
compared to either of the other 2 subsets.  The CD14dim/CD16+ group do express 
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more anti-inflammatory cell surface markers such as IL-10 and match to their human 
counterpart CD14dim/CD16+. 
 
Immune response to peritonism 
It is surprising given the potential that the effect of surgery or tissue damage on the 
immune response has not been studied more.  There are several different animal 
models that have demonstrated recruitment of cells to the peritoneal cavity but there 
has been little published regarding the effects this has in a more global sense.  There 
are over 800 publications in pubmed that have used the ceacal ligation and puncture 
model and this is probably the most widely used (138).  The problem with CLP is that 
there are several facets to it, incision, ligation and puncture all of which can be 
performed in a slightly different way dependent on local protocol.  It remains a good 
model for examining the pathophysiology of sepsis in general but diificult to tease out 
which facet is responsible for recruitment or activation of leucocytes.  
Other animal models have also looked at the trafficking of leucocytes into the 
periotneal cavity and the gut.  To examine the effect this migration has on gut motility 
Kalff et al performed a laparotomy, handled the gut, closed and then removed the gut 
at various timepoints, measuring the amount of leucocyte activation in the muscularis 
mucosa (139).  In a later study they found greater numbers of monocytes and 
macrophages in peritoneal lavage fluid after surgery upregulating COX-2 expression 
and suggested as a putative mechanism for post-op ileus (140).  Many of the studies 
utilising CLP have a control group undergoing a sham laparotomy, these often 
demonstrate recruitment of monocytes and neutrophils when compared to wild type 
animals  (141).    These effects are a combination of the trafficked immune cells and 
the resident cells.  There is some evidence that activation of immune cells in the 
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peritonal cavity can have deleterious effects at distant organ sites such as the heart 
(142) and lung (143).  By removing at least some of the resident cells prior to 
introduction of LPS, Zhao et al found that mice could be partially protected (144).  
Either LPS or surgery are able to recruit cells to the peritoneal cavity.  Further 
stimulation provides a mechanism by which multi-organ failure could be triggered. 
The kinetics and trafficking of leucocytes to the peritoneal cavity is difficult to study 
in humans not just because of patient heterogenaity but also the variation in surgery 
and technique.  There are studies that have examined blood monocytes and the 
expression of HLA-DR following abdominal surgery (145) and more recently the 
influence of leucocytes on the development of multi-organ failure in the trauma 
patient (146).  However the majority report the effect of surgery or its complications 
on hard outcomes for patients, which are clearly important, rather than the process of 
recruitment and activation within the peritoneal cavity and translation of this into a 




1. In response to mild surgical trauma there is differential migration of the 
monocyte subsets into the peritoneal cavity.  
2. Monocytes are primed by migration to produce more TNF when exposed 
to a post-operative infection. This production of pro-inflammatory 
cytokines, given the right circumstances, provides a mechanism for the 
development of multi-organ failure. 
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Monocyte subsets have been delineated for some time; there has been an appreciation 
more recently that the speed of migration into areas of inflammation is more rapid 
than originally thought.  In combination with a priming effect from endothelial 
rolling/binding prior to extravasation this provides a discreet but potentially critical 
upstream event in subsequent peritonitis and sepsis.  Several animal models have 
observed this infiltration of monocytes but not defined it. 
Clinically, the description of cell migration and activity following minor surgery will 






































Invitrogen (Paisley, UK) supplied Dulbecco’s phosphate buffered Saline (PBS), 
Foetal Calf serum (FCS) and Hanks Balanced salt solution (HBSS). 
Ethylenediaminetetraacetic Acid (EDTA), sodium azide and Trypsin-EDTA were 
purchased from Sigma chemical company (Dorset, UK).  Lyse-fix solution was 
supplied by BDbioscience (Oxford, UK).  The metalloproteinase inhibitor BB94 was 
obtained from British Biotech (Oxford, UK).  FACS Wash buffer (FWB) was the 
main solution used to harvest, wash and suspend cells.  It contains 2% foetal calf 
serum, 5 mM EDTA, 0.1%Azide diluted in PBS.  LPS ultrapure (E. Coli 0111:B4) 
was purchased from Autogen Bioclear (Wiltshire, UK)) 
 
Animals 
All protocols performed were in accordance with the Animals (Scientific Procedures) 
Act 1986, United Kingdom and had previously been reviewed and approved by the 
Home Office.  Experiments were performed using male C57BL/6 mice (Charles 
River, Margate) between 8 to 12 weeks of age.   
 
Antibodies 
All antibodies were flurophore-conjugated for use in flow cytometry and directed 
against murine antigens.  For determining expression of cell surface proteins (eg 
TNFα) appropriate isotype-matched controls were used utilizing flurophores not 
involved in cell identification.  By subtracting the amount of flurophore detected with 
the isotype controls from the actual samples the signal from non-specific binding can 
be removed.   The antibodies used are listed in Table 1.  
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Antibody Flurophore Clone Manufacturer Description Isotype 
































Table 1. Murine antibodies used with their associated flurophore and the 
manufacturer. FITC – Fluorescein isothiocyanate; PerCP – Peridinin Chlorophyll; 
PE – Phycoerythrin; APC – Allophycocyanin.  
 
Peritoneal LPS 
LPS was diluted to the required concentration in sterile PBS.  200µL of solution was 
prepared in an insulin syringe to minimise damage to the peritoneal wall during 
injection.  The solution was injected into the left upper quadrant of the animal’s 
abdomen.  They were allowed to recover in a warm cage with unlimited supply of 
water and food. 
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Surgery 
Animals that underwent surgery were anaesthetized using a gas chamber filled with 
isoflurane until there was no response to pedal pressure, they were then transferred to 
a heated matt within a sterile area.  Anaesthesia was maintained using isoflurane in a 
50:50 O2, and air mix via a sterile glove modified to act as a mask.  Spontaneous 
breathing was maintained and therefore no muscle relaxant was required.  Expired gas 
was analysed to keep the minimum alveolar concentration (MAC) between 1.6 and 
2.0.  Prior to surgery a lack of response to pedal pressure was again used to indicate 
sufficient depth of anaesthesia.  Further monitoring included tail O2 saturation and an 
intramuscular temperature probe. 
Once anaesthetised and monitored the abdomen was shaved and the skin prepared 
using aqueous betadine (Ecolab, Leeds, UK).  The area around the mouse remained 
sterile using a paper drape and the operator used sterile gloves to maintain an aseptic 
field.  A longitudinal skin incision was performed in the upper left quadrant with a 
size 11-scalpel blade and extended to approximately 2cm.  For peritoneal incision, 
blunt dissection to expose the bowel and intra-abdominal organs was performed and a 
further 2cm incision completed.  The peritoneum was opened for a maximum of 3 
minutes following the initial incision.  The layers were then closed individually using 
4.0 silk, interrupted sutures for the peritoneum and 2.0 silk continuous sutures for 
skin. A 5% eutectic mixture of local anaesthetic (Astra Zeneca, London, UK) was 
applied topically to the wound as analgesia. Anaesthesia was discontinued and the 





Peritoneal Lavage Protocol 
Mice were sacrificed by isoflurane overdose and exsanguinated by cardiac puncture 
including 10IU of heparin.  An initial 5ml of FWB was injected using a 23G needle 
into the peritoneal cavity and the mouse was agitated for 1 minute to distribute cells.  
This initial lavage was aspirated, and the procedure repeated with a further 5ml of 
FWB.  The recovered lavage and blood sample were stored on ice.  
 
Flow cytometry 
The lavage and blood samples were first centrifuged for 10mins at 2000rpm and re-
suspend in 200uL of FWB.  The samples were combined with 50µL of antibody or 
isotype control and incubated at 4°C in the dark for 30 minutes. The cells were 
washed and re-suspended in 50µL of FWB.  Prior to re-suspension, red blood cells 
were lysed using BD lyse/fix and the samples washed again. 
Flow cytometry was performed on a Cyan flow cytometer (Beckman Coulter, High 
Wycombe, Uk) and the data analysed using Flowjo software (Treestar, Oregon, US).   
The gating strategies used were subjective (147), accepting that the gates may be 
altered to include cells forming distinct populations.  They were based on the 
distribution of cells in the blood of normal untreated mice.  Previous established 
gating strategies (120,132,148) were modified to identify the recruited subpopulations 
in the peritoneal lavage fluid.  The results are present as the number of cells per ml. 
 
Detection of membrane bound TNFα. 
To try and reduce the confounding of LPS and TACE activity on the amount of 
membrane bound TNFα expressed the metalloproteinase inhibitor BB94 was included 
with the lavage fluid at a concentration of 10uM.  Cell counts were not affected by its 
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inclusion in the lavage fluid.  The process of preparation and flow cytometry then 
continues as above.   
Expression levels are given as the geometric mean of fluorescence intensity (MFI) 
emitted by cells, with the isotype control value subtracted. Results are reported as 
mean of repeated experiments ± SEM. 
 
Ex-Vivo stimulation of peritoneal lavage cells 
The variation in the methodolgy with the ex-vivo experiments were as follows.  In 
these animals, 24 hours after surgery lavage fluid was obtained using RPMI rather 
then Facs Wash Buffer (FWB).  This allowed the cells to be maintained whilst 
stimulated by LPS ex-vivo.  The cell counts were obtained using a haemocytometer 
and then incubated at 37°C either with the TACE inhibitor BB94 or 0.9% saline in 
equal volume and either 20ng LPS or an equal volume of 0.9% saline for one hour.  
The samples were centifuged at 1200rpm for 5 mins and the supernatant separated 
from the cells.  The cells were re-suspended in FWB and then stained for 
flowcytometry in an identical way to that described above.  In those samples not 
incubated with BB94 the supernatant was removed and stored at -20°C for later 
analysis of soluble TNFα by ELISA as descibed below. 
 
ELISA of soluble TNFα 
This was performed using our in-house assay with reagents purchased from R&D 
systems.  
ELISA  plates  (Nunc,  Roskilde,  Denmark)  were  coated  with  capture 
antibody  (R&D)  at  1µg/ml and left at 4°C for 16 hours. Wells were then washed x 4 
with PBS supplemented with 0.05% Tween-20 (Sigma), this washing protocol was 
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automated as standardised throughout the protocol. Wells were then blocked for an 
hour using a PBS supplemented with 1% BSA (Sigma) and 0.05% Tween-20 (Sigma). 
The washing step was repeated before standards consisting of TNF (R&D) were 
added. Samples were added and diluted in block buffer where appropriate and 
incubated for 2 hours at room temperature. Plates were then washed and biotinylated 
antibody (R&D) added at 200ng/ml and then left for a further two hours. Plates were 
washed once again and streptavidin-HRP (R&D) was added at a 1/200 dilution and 
left for 20 minutes. Substrate solution - Tetramethylbenzidine(TMB) (Sigma, UK) 
was added and plates incubated in the dark for a further 20 minutes before 2M 
Sulphuric acid (VWR, Leicestershire UK) was added as a stop solution. 
Plates were read using a Dynex MRX II plate reader (Worthing UK) in conjunction 
with RevelationTM software (version 4.22, Dynex). 
 
Wet/Dry Ratios 
Animals were sacrificed by a recognised schedule one method and the lungs dissected 
out, ensuring the hilar structures were avoided.  The lungs were then weighed to 
calculate the wet weight and then dried for 4 hours and weighed again to calculate the 
dry weight.  The difference between these two weights represents the amount of fluid 
in the lungs.  This technique proved difficult and the results often hard to interpret as 
there was wide variance in repeat experiments.  Because of this wet/dry ratios were 






Lung Permeability Index 
An alternative method of calculating the amount of peri-capillary leak is to utilise 2 
separate dyes attached to flurophoes of different wavelengths (149).   
The first dye, Alexa Fluro 594 (Invitrogen, Paisley, UK) is mixed with Bovine serum 
albumin (BSA) and injected into the tail vein, it circulates for 2 hours and a 
proportion crosses the pulmonary endothelium.  To exclude the influence of 
intravascular BSA in the residual blood left in the lung samples, mice were injected 
i.v. with a second dye, Alexa Fluor 488-conjugated BSA (0.2 mg/mouse; Invitrogen) 
along with heparin (100 U/ml) 5 min before sacrifice.    
Lungs were excised, rinsed briefly in saline, and swabbed gently with tissue to 
remove surplus blood. Lungs were then homogenized and incubated with collagenase 
type IV (Sigma-Aldrich) for 30 min at 37°C to ensure release of tissue-sequestered 
BSA. After further homogenization, lung suspensions were passed through a 50um 
filter and centrifuged,  supernatants were collected. Fluorescence levels were 
measured in lung homogenate supernatants and diluted whole blood samples (1/100) 
using a fluorescence plate reader (Flx-800; Bio-Tek Instruments). An index of 
vascular permeability was calculated by subtracting the lung:blood ratio of BSA-
Alexa Fluor 488 nm (intravascular content) from the lung:blood ratio of BSA-Alexa 
Fluor 594 nm (total lung content). 
 
Statistics 
The data is presented as the mean of the repeated experiments ± SEM.  Each 
collection of data was analysed for normality using the Kolmogorov-Smirnov test. 
Parametric data was analysed using an unpaired t-test for 2 variables and one-way 
ANOVA with Bonferroni correction for multiple comparisons if there were 3 or more 
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variables. Non-parametric data were analysed with a Mann-Whitney U test for 2 
variables and Kruskal-Wallis test with Dunn’s test for multiple comparisons for more 
than 2 variables.  The analysis was performed using Prism software (Graphpad, 
USA). p values less than 0.05 were considered to be significant. 
In order to reduce the number of animals required for these experiments the control 



































Background and aims. 
In-vivo studies on the recruitment of monocytes to areas of inflammation have been 
performed mostly in mice using both whole bacteria and specific PAMPs such as 
LPS.  Van Furth described the use of thioglycollate broth as an intra-peritoneal 
injection, designed to increase the number of peritoneal macrophages for in-vitro co-
cultures (150).  Thioglycollate increases the number of peritoneal leucocytes within 
the first 48 hours but these cells are not activated (ie minimal opsonisation of bacteria 
or production of pro-inflammatory cytokines). More recently, Geissman’s group used 
sterile intra-peritoneal thioglycollate to create an inflammatory response to observe 
the kinetics of the monocyte subsets.  In a similar way Sunderkotter used ip sterile 
foetal calf serum (120,121,135).  Although this sets up a sterile inflammatory 
response it does not represent the commonest cause of intra-peritoneal inflammation 
which is infection.  The processes of mononuclear cell recruitment, migration and 
differentiation related to an infected stimulus are likely to be different to that from a 
sterile stimulus.  In the abdomen most infections occur due to peritoneal seeding of 
gram negative commensal gut flora either via translocation or direct spill over from a 
perforated viscus.  As previously mentioned the model of caecal ligation and puncture 
combines the effects of surgery and peritoneal infection making inferences about the 
effects of each component difficult to make.  Feacal pellets are available but it is hard 
to standardise the numbers of microbes within them. Although less representative of 
the gut flora antigens, local administration of purified bacterial PAMPs such as LPS 
offers a more precise way of defining the peritoneal and systemic response to an 
infected peritoneum.  
Van Furth also used sterile foetal calf serum to evoke peritoneal inflammation and 
demonstrated the flow of murine mononuclear cells from bone marrow through blood 
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monocytes to tissue macrophages (151)(96). This process invovles CCR2 (Chemokine 
receptor 2) and its ligand MCP-1 (Monocyte chemoattractant protein-1) (152). One 
trigger for release of monocytes appears to be from small amounts of microbial 
components such as LPS that enter the circulation and increase expression of MCP-1 
on mesenchymal cells within the bone marrow (153).  LPS injected into the 
peritoneum is able to rapidly pass into the circulation (154); Shi et al performed a 
dose response experiment and the intra-peritoneal dose mobilising the greatest 
number of bone marrow monocytes was 20ng (153).  Monocytes are released at doses 
less than this but at higher doses monocytes are sequested in bone marrow and lung 
vasculature (155).  The monocytes mobilised by intra-peritoneal LPS appear to have 
effects at distal sites such as the lung (156).  This may be a function of monocytes 
released into the circulation by any inflammatory process or it may be unique to intra-
peritoneal infection.  Intra-peritoneal LPS has been shown to trigger monocyte release 
from bone marrow but there is also a suggestion that monocytes may also be released 
from a splenic store (126) in response to inflammation.   The degree of LPS spill over 
from the peritoneal cavity may influence the response to the source infection as well 
as the level of systemic response.  As TLR-4 is expressed on circulating immune cells 
and endothelial cells the pulmonary endothelium acts as sentinel cells for systemic 
infection leading to margination of leucocytes in the pulmonary vasculature.  Barrier 
site infection such as within alveoli or peritoneal cavity relies on bone marrow 
derived immune cells such as monocytes and macrophages to detect microbes and 
recruit cells to the areas of inflammation.  Ironically the global actiavation and 
sequestration of leucocytes with systemic disease may actually delay the clearance of 
the original infection (157). 
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Aim 1. Examine the dose-response relationship of intra-peritoneal LPS 
leading to monocyte recruitment and describe the time course for each of the 
monocyte subset’s migration from blood into the peritoneal cavity 
 
Monocytes migrate into the peritoneum in reponse not only to infection or sterile 
inflammation but also tissue damage, such as that caused by surgery or trauma 
(42,43,158).  In response to microbial invasion the innate immune system is activated 
by pathogen associated molecular patterns (PAMP’s) such as LPS.  The cell damage 
as a result of surgery or trauma is sterile, but the innate immune system can still be 
activated via the recognition of damage associated molecular patterns (DAMP’s) such 
as high mobility group box 1 protein (HMGB), ATP and nucleic acids.  These 
constituent parts of cells are able to trigger pattern recognition receptors and activate 
the innate immune system.  There is some cross-over in the recontion of DAMP’s and 
PAMP’s, for example TLR-4 recognioses both LPS and HMGB (43).  Levels of 
HMGB-1 correlate with injury severity score and base deficit following trauma 
(159,160), and are raised after haemorrhagic shock (161).  Although many of the 
other DAMPs do not correlate well with injury severity this provides some evidence 
for the triggering of the immune response by the insult of tissue damage (146).  There 
are several other compounds that seem to act synergistically as DAMPs when 
triggered by tissue damage.  These include ATP (162) which on release from necrotic 
cells recruits neutrophils to adhere to endothelium surrounding the areas of necrosis 
and formyl peptides that form a chemokine gradient promoting neutrophil migration 
to the areas of necrosis (163).    
The response to PAMPs is subtly different to the response to DAMPs but there is also 
a degree of mutual activation, monocytes adherent to endothelium in repsosne to LPS 
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will upregulated a receptor for HMGB-1  (164).  The differences may be related to the 
levels of potency.  LPS is a potent stimulus that when present in the circulation will 
lead to a widespread response.  DAMPs however are less potent and tend to limit the 
reaction of the innate immune cells to local areas of necrosis. 
 
Aim 2. Compare and contrast the recruitment of monocytes to the abdominal 
cavity when stimulated by surgery to recruitment triggered by LPS.  
 
Protocols 
Intra-peritoneal LPS stimulation 
The protocols for the injection of LPS and the harvest of cells from blood and 
peritoneal lavage were described in detail in chapter 2.  C57/B6 mice received 
peritoneal LPS at 2 different doses.  These doses were based on the work showing 
maximal monocyte margination to the lungs at a sub-clinical dose of 20ng LPS intra-
venously and clear clinical symptoms produced with 20µg  intra-venous LPS (132) 
and is consistent with Shi et al who subsequently found maximal release of 
monocytes from bone marrow with an intra-peritoneal dose of 20ng LPS (153). 
By sacrificing the animals at a variety of time points up to 48 hours the time course of 
migration for each monocyte subset can be calculated. 
 
Surgery 
The surgical protocol developed has been described in detail in chapter 2.  The 
animals undergoing peritoneal incision were compared to two control groups; one 
receiving a skin incision alone and the other receiving anaesthesia for a period 
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approximate to the duration of the anaesthesia for the surgical group.  The animals 
were sacrificed at time points up to 48 hours.  
 
Results 
Identification of monocytes in blood and peritoneal lavage samples using flow- 
cytometry following ip LPS. 
As previously reported there is an established method for identifying monocytes in 
murine blood samples with flow cytometry based on side scatter (cell granularity), the 
surface expression of CD11b and the monocyte/macrophage marker F4/80 
(132,135,165).  The CD11b+ cells are neutrophils, monocytes, eosinophils or natural 
killer cells and these can be differentiated by the use of F4/80 and side scatter 
(granularity) (166).  A clear reproducible population of monocytes is easily 
differentiated from lymphocytes (CD11b-), neutrophils (CD11b+, F4/80, Gr-1Hi++), 
eosinophils (CD11b+, F4/80+, high side scatter) and natural killer (NK) cells (CD11b+, 
F4/80-, Gr-1Lo-Med) (Figure 1). The monocyte population (CD11b+, F4/80+) can be 
divided into two subpopulations, Gr-1Lo and Gr-1Hi.  In response to low dose (20ng) 
ip LPS, there wasn’t a significant change in monocyte subset numbers (n=3-5), but 






Figure 1.  Identification and quantification of circulating monocytes.  Blood was 
obtained from controls (A) and from animals injected with 20ng ip LPS 24 hours 
previously (B).  Monocytes were identified as CD11b+ and F4/80+.  R1 CD11b+; R2 
Neutrophils; R3 Gr-1Hi monocytes; R4 Gr-1Lo monocytes.  There is no significant 
difference in blood monocyte cell number between controls and 20ng ip LPS (C). Un-
















In peritoneal lavage from normal mice there was a resident population of cells that are 
strongly positive for CD11b and also express F4/80, these cells have previously been 
described as resident macrophages (135).  There are also a resident population of Gr-
1Lo cells that resemble Gr-1Lo monocytes in blood and are distinct from macrophages; 
there are few or no Gr-1Hi monocytes.  At 24 hours after a 20ng dose of ip LPS there 
was a rise in peritoneal lavage cell numbers with additional phenotypes clearly 
apparent.  The CD11b+ cells can be further separated by their expression of F4/80 and 
Gr-1.  Neutrophils were evident with a similar phenotype as in blood of F4/80- and 
Gr-1Hi, while the monocytes classified by medium expression of F4/80 were mainly 
of the Gr-1Lo phenotype (Figure 2).  Despite the prominence of Gr-1Lo subset 
phenotype, relative increases in the Gr-1Hi cells were much higher due to their virtual 





Figure 2.  Identification and quantification of peritoneal lavage monocytes.  Lavage 
was obtained from the peritoneum of both controls (A) and mice that received a 20ng 
ip injection of LPS 24hrs previously (B).  The cell populations were described in a 
similar way to the populations found in blood.  R1 CD11b+; R2 Gr-1Lo monocytes; R3 
Gr-1Hi monocytes; R4 Peritoneal macrophages; R5 Neutrophils There are more 
monocytes of both subsets present in lavage following LPS exposure than are found in 
normal control mice(C). Un-paired t-test Gr-1Hi p=0.009;Gr-1Lo p=0.02; n=5control 
and 8intervention. 
 
To further evaluate and understand the changes in peritoneal populations, peritoneal 
lavage fluid following injection of ip LPS was examined at various time points up to 
48 hours (Figure 3 and 4).  Blood monocyte counts appeared to rise at 16-24 hours, 
but no clear pattern emerged over the 48 hour observation period. 
Mirroring this apparent increase in circulating cells, in peritoneal lavage fluid there is 
an initial rise in Gr-1Hi monocytes peaking around 16 hours and subsequently 
declining by 48 hours.  The peritoneal lavage fluid Gr-1Lo monocytes initially decline 
















results suggest that the Gr-1Hi subset is preferentially recruited initially following an 
infective stimulus but this process is transient.  The Gr-1Lo monocytes numbers also 
increase somewhat later; this may represent either in-situ maturation or a second wave 





Figure 3.  Monocyte subset kinetics in blood after ip LPS.  The change in monocyte 
subset numbers were followed in blood over 48hours after an ip injection of 20ng LPS 
and compared to control animals not exposed to LPS.  One-way ANOVA Gr-1Hi 






















Figure 4.   Recruitment kinetics of monocytes to the peritoneal cavity after ip LPS.  
The change in monocyte numbers was tracked in peritoneal lavage fluid at various 
time points over 48 hours. Kruskal-Wallis Gr-1Hi p=0.0005; One-way ANOVA Gr-1Lo 
p=0.01.  *p<0.05. n=3control and 5intervention. 
 
The dose of 20ng LPS recruits monocytes to the peritoneum following intra-
peritoneal injection without any significant change in the number of circulating cells. 
In contrast, LPS triggered an early increase in the number of neutrophils in both blood 
and peritoneal lavage at 2 hours indicating that this dose was sufficient to elicit a 
systemic response (Figure 5 and 6).  The increase in blood was completely reversed 
by 16 hours but persisted in the peritoneal lavage fluid.  These results are consistent 
overall with the typical neutrophil then monocyte sequence of migration (49), without 
clear evidence of early monocyte emigration as described by Auffray (121). There 
were significantly more macrophages within the peritoneal lavage both in the control 
animals and after LPS when compared to monocytes or neutrophils.  Following LPS 
there was a decrease in the number of peritoneal macrophages reaching a nadir 















between 2 and 16 hours.  This is likely to represent the previously described 





Figure 5.  Neutrophil kinetics in blood after ip LPS.  The change in neutrophil 
numbers in blood over time following a 20ng intra-peritoneal LPS challenge 
compared to control animals. One-way ANOVA p=0.03; *p<0.05 compared to 




































Figure 6.  Neutrophil and resident macrophage kinetics in the peritoneal cavity 
after ip LPS.  A comparison of the absolute numbers of neutrophils and macrophages 
found in peritoneal lavage following a 20ng intra-peritoneal LPS challenge compared 
to control animals. One-way ANOVA PMac p=0.01; PMN p=0.002. *p<0.05 
compared to control. n=3control and 5intervention 
 
Leucocyte peritoneal migration with high dose ip LPS 
The numbers of cells recruited in response to intra-peritoneal saline, a sub-clinical 
20ng dose of LPS or a clinical 20µg dose of LPS were compared (Figure 7).  
Clinically there was a difference between the mice exposed to the 20ng dose and the 
mice exposed to the 20µg dose.  The latter demonstrated piloerection and reduced 
movement whereas the former were indistinguishable from control animals. 
 

















Figure 7.  Leucocyte recruitment following high and low dose ip LPS challenge.  
The recruitment effect of either control 0.9% saline, 20ng LPS or 20µg LPS on 
myeloid leucocyte subpopulations in (A) blood and (B) peritoneal lavage fluid 24 
hours following injection.  Blood – (One-way ANOVA) Gr-1Hi 0.1; Gr-1Lo 0.07; PMN 
0.1.  Lavage – Gr-1Hi (unpaired t-test) p=0.04; Gr-1Lo (One-way ANOVA) p=0.001; 
PMN (unpaired t-test) p=0.63; PMac (One-way ANOVA) p=0.03. 
 
With the high dose of 20µg ip LPS the circulating monocytes decrease whilst the 
neutrophil counts remain the same.  In the peritoneal lavage fluid there was an un-
expectant reduction in monocyte numbers with the high dose LPS.   This may be 
related to more overspill of LPS into the systemic circulation leading to greater 
sequestration in the pulmonary vasculature or an effect similar to the macrophage 
disappearance reaction acting on the trafficked monocytes. 
There was little difference in the numbers of neutrophils at either dose and there were 
less peritoneal macrophages at both doses than the control animals in keeping with the 


















Leucocyte recruitment to the peritoneal cavity following abdominal surgery and  
their identification by flow cytometry. 
Following surgery the analysis of the flow cytometric data was more complex than 
the analysis following an LPS challenge.  This complexity appeared to derive from 
the higher numbers of CD11b+ cells that migrated into the peritoneal cavity and the 
more diverse phenotypes as based on the CD11b and side scatter (granularity) plots 
(Figure 8 and 9).   The flow cytometry plots for the mice receiving a skin incision 








Figure 8.  Identification of Cd11b+ cells in peritoneal lavage fluid.  Mice either 
received a skin incision alone (A) or a full thickness incision through peritoneum (B).  
At 24 hours peritoneal lavage samples were obtained.  These populations are more 
difficult to differentiate due to significant overlap in expression of surface markers. 




Figure 9.  Flow cytometric analysis of peritoneal CD11b+ populations following 
abdominal surgery.  24 Hours after peritoneal incision mice were sacrificed and 
peritoneal lavage obtained.  Several overlapping CD11b+ populations can be 
identified by flow cytometry. High side scatter cells would be consistent with 
neutrophils (Gr-1Hi, F4/80-) and eosinonphils (F4/80+, Gr-1Med-Lo) (148).  The cells 
with less side scatter would be consistent with monocytes (F4/80+, variable Gr-1 
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expression), and natural killer cells (F4/80-, Gr-1-). The population with the highest 
expression of CD11b and variable side scatter would be consistent with peritoneal 
macrophages. R4 Peritoneal macrophages; R5 Eosinophils; R6 Neutrophils; R7 
Monocytes; R8 Natural killer cells. 
 
A particular uncertainty was created by F4/80 monocyte/macrophage marker because 
of its known cross-reactivity with eosinophils (168).  To improve delineation of 
mononuclear phagocytic population from other cell types in resting and inflamed 
peritoneum, staining for CD115, the monocyte colony stimulating factor (M-CSF) 
receptor present on cells of the monocyte/macrophage lineage was included.  The 
populations were gated into CD11b+, CD115+ (monocytes, resident macrophages) or 
CD11b+, CD115- (non monocyte/macrophage) (Figure 10).  This strategy allows easy 
identification of both subsets of monocytes as well as peritoneal macrophages in 
lavage samples but it does not distinguish between resident and recruited macrophage 









Figure 10.  Flow cytometric analysis of peritoneal CD11b+ populations using 
CD115 expression to identify mononuclear phagocytic cells.  Animals were 
sacrificed 24 hours after peritoneal incision.  CD11b+ peritoneal lavage cells were 
stained and gated as either CD115+ (monocytes and macrophages (MΦ)) or CD115- 
(neutrophils and eosinophils).  These cells were then gated as previously with F4/80 
and Gr-1. R1 CD115-; R2 CD115+; R3 Neutrophils; R4 Eosinophils; R5 Gr-1Hi 
monocytes; R6 Gr-1Lo Monocytes; R7 Peritoneal macrophages 
 
This new strategy allowed a more accurate estimation of monocyte migration 
following surgery.  The essential stimulus for migration in the surgical model was the 
peritoneal incision; animals receiving skin incision alone or anaesthesia alone did not 





Figure 11. Leucocyte recruitment to the peritoneal cavity with variation in surgical 
stimulus.  Animals were separated into 3 groups. Anaesthesia alone, Anaesthesia + 
skin incision, Anaesthesia + skin incision + Peritoneal incision.  At 24 hours 
peritoneal lavage was obtained. Kruskal-Wallis Gr-1Hi p=0.003; Gr-1Lo p=0.003; 
PMN p=0.003; PMac p=0.29. n=3control and 18intervention 
 
Kinetics of monocyte trafficking to the peritoneal cavity following abdominal  
surgery.    
Following laparotomy, monocyte subset dynamics in the blood and recruitment to the 
peritoneum was assessed at a variety of time points over 48hours. 
There was little variation in Gr-1Hi monocytes in blood although the Gr-1Lo monocytes 
were significantly reduced in the first 4hrs following surgery (Figure 12). 
There was a similar pattern in terms of recruitment of monocytes to the peritoneal 
cavity following surgery (Figure 13) as there was following intra-peritoneal LPS 




























not possible to perform a time point that was comparable to that used in the LPS 
animals, as the mice needed time to recover from surgery. The onset of recruitment is 
slower when the stimulus is surgery than when the stimulus is LPS.   
There were significantly more Gr-1Hi monocytes recruited to the peritoneum after 
surgery than after ip LPS (20ng) challenge (LPS 2.45±0.55×105 vs. surgery 
7.27±1.88×105  p=0.03) at 16h post-treatment. By 24 hours this difference between 
the two challenges was apparent with the Gr-1Lo subset numbers (LPS, 1.90±0.34×105 




Figure 12. Monocyte subset kinetics in blood after abdominal surgery. The change 
in monocyte numbers were followed in blood over 48 hours after an ip injection of 
20ng LPS and compared to control animals not exposed to LPS. One-way ANOVA 























Figure 13.  Recruitment kinetics of monocytes to the peritoneal cavity after 
abdominal surgery.  The change in monocyte numbers was tracked in peritoneal 
lavage fluid at various time points over 48 hours.  They were compared to control 
animals that did not undergo surgery.  Kruskal-Wallis Gr-1Hi p=0.0001. *p<0.05 
compared to control animals; Gr-1Lo p=0.0001. **p<0.05 compared to control 
animals. n=5control and 6intervention. 
 
In contrast to blood monocytes, neutrophil numbers present in blood increased 
significantly at 4 hours and appeared to remain elevated for the duration of the time 
course (Figure 14). In peritoneal lavage fluid, neutrophils increased significantly 
following surgery but with much larger variation between mice than found with 

























































macrophages reaching a nadir between 8 and 16 hours suggesting surgery is also a 




Figure 14.  Neutrophil kinetics in blood after abdominal surgery. The change in 
neutrophil numbers in blood over time following abdominal surgery compared to 
control mice.  One-way ANOVA p=0.001. * p<0.05.  n=3control and 5intervention. 
 
 




































































Figure 15. Neutrophil and resident macrophage kinetics in the peritoneal cavity 
after abdominal surgery. A comparison of the absolute numbers of neutrophils and 
macrophages found in peritoneal lavage following abdominal surgery compared to 
control animals.  PMN Kruskal-Wallis p=0.01; PMac One-way ANOVA p=0.03. 
* p<0.05 n=3control and 5intervention. 
 
Discussion 
Murine monocyte subsets have been described in blood and have different functional 
phenotypes (120,123,126,148).  This heterogeneity can affect the inflammatory milieu 
at local sites of inflammation including the ovary (169) kidney (170), lung (132) and 
the peritoneal cavity (121).  The Gr-1Hi subset are released from both bone marrow 
and spleen in response to inflammation and become the more pro-inflammatory 
phenotype when migrating into tissues.  They are the predominant producers of TNFα 
(121,171), they differentiate into macrophages of the classic M1 phenotype (172) and 
may also suppress tumor growth (173).   The Gr-1Lo phenotype may be more likely to 
differentiate in to cells with reparative capacity, in the peritoneum they differentiate 
into macrophages of the alternative pathway, M2 (172) and are late migrators into 
myocardium after ischemia promoting fibrosis (127).  The dynamics of monocyte 
subset recruitment to the peritoneum following surgery are likely to be highly 
significant in the development of subsequent peritonitis.   
 
The differences in response of the monocyte subsets were demonstrated by comparing 
a conventional PAMP in the form of LPS to a sterile surgical procedure.  The 
qualitative and quantitative differences observed were surprising as irrespective of the 
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dose of LPS, surgery elicited greater monocyte recruitment.  Previous work has 
suggested that LPS from areas of inflammation triggers monocyte release from bone 
marrow even at ip doses as low as 2ng (153), given the presence of DAMPS such as 
HMGB in plasma with a half-life of 17 minutes (174), a similar effect could also 
occur with surgery.  These cells originating from the bone marrow increase the 
circulating pool; although our data confirm this for neutrophils at 2 hours there is no 
significant change in blood monocytes of either subset.  This may be because the 
change is small and very transient; the released cells rapidly extravasate into the areas 
of infection along a chemokine gradient (49). 
The pattern of recruitment of monocytes to the peritoneal lavage fluid mirrors that of 
blood although the numbers and degree of change is greater in lavage fluid, this may 
be because these cells are trapped in the cavity and, unlike the circulating cells cannot 
marginate to other capillary beds (132,157).  A similar pattern of recruitment is seen 
whether the stimulus is LPS or surgery.  However there are many more leucocytes 
that migrate to the peritoneum after surgery with a greater proportion expressing 
CD11b, requiring an alternative strategy to identify the subpopulations. 
Of note both the resident peritoneal macrophages and Gr-1Lo monocytes (that may 
well be resident) are reduced from baseline at early time points following either LPS 
or surgery.  Barth describes a peritoneal ‘macrophage disappearance reaction’ (MDR) 
that can occur with either inflammatory macrophages or as in this case with the 
resident population (167).  LPS is known to trigger this reaction (175).There is some 
evidence that the mechanism of the “MDR” involves the coagulation system, it can be 
reversed by heparin and warfarin (176), fibrin is present on macrophages attached to 
the peritoneum (177) and there is evidence of fibrinolysis as the reaction resolves 
(178).  It is hypothesized that the increased adhesion of macrophages to the peritoneal 
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lining makes accurate recovery difficult.  Previous authors have found the reaction 
reverses by 48 hours (179) and our work would be consistent with this.  
The process of recovery of cells from the peritoneal lavage is critical to this work.  
The risks of using systemic or local anti-coagulation in the immediate post-operative 
period outweighed the potential benefits in terms of cell recovery.  The potential to 
improve the number of cells recovered enzymatically using trypsin was attempted but 
had no effect.  The danger of manipulating the macrophage ‘stickiness’ is that the 
process may also affect the identification of cells or their inflammatory phenotype. 
In humans there is clear myeloid migration to peritoneal fluid after gastrointestinal 
surgery although many are strongly adherent to peritoneum and difficult to harvest 
(180).  These cells are the main producers responsible for the increase in soluble 
TNFα and IL-6, the increase in class II macrophages and the increased expression of 
HLA-DR on trafficked monocytes. 
 
There are several candidates that may act as sentinel cells including macrophages, 
mast cells (181) and endothelium; via the expression of TLR-4.  The toll-like 
receptors detect LPS but are also able to detect DAMPs such as HMGB and heat 
shock proteins (182,183). Monocytes are known to express pattern recognition 
receptors including TLR-4, their fate is dependent on the chemokine environment as 
well as their subset phenotype (184).  For example monocytes exposed to LPS, IFNδ 
and M-CSF differentiate into M1 macrophages whereas exposure to IL-4 promotes 
differentiation into M2 (185). The differential effects of the monocyte subsets are 
mediated by expression of cell surface proteins, CCR2 on Gr-1Hi and CX3CR1 on the 
Gr-1Lo and the interaction with their ligands MCP-1 and fractalkine (97,186,187).  
There is no evidence in either LPS or surgically stimulated animals that the sentinel 
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event is early migration of patrolling Gr-1Lo cells as described by Auffray but the cell 
counts in their experiments were at least one order of magnitude lower (121).  This 
may be because the insult of surgery or LPS is different to the sterile injection of 
Thioglycollate used by Auffray.  If this occurs at all then it is likely to be dwarfed by 
the later migration of Gr-1Hi cells.  Although there is evidence of in-situ maturation 
from the Gr-1Hi monocytes to the Gr-1Lo subset in other models of inflammation 
(127,129,135) it is not possible to clarify this with our model.  It is possible that there 
is some maturation that occurs but also a separate kinetic of Gr-1Lo monocytes from 
the circulating pool, the factors promoting each process are currently unknown.(121). 
 
Surgery induces a greater recruitment of inflammatory cells than the doses of LPS 
studied.  It may therefore prime the peritoneal cavity to respond more aggressively 
both locally and systemically to a subsequent breach of the gastrointestinal tract and 
release of bacteria.  This in turn may create the ideal environment for the development 





















The local and systemic response of monocytes to LPS 










Background and aims  
We found that a surgical incision which opens the peritoneal cavity produces a 
substantial infiltration of inflammatory cells including monocytes and neutrophils.  
The pattern of monocyte subset recruitment shares some similarities with the 
recruitment generated by the prescence of LPS, however, there are also important 
differences.  There appeared to be a greater number of cells that traffic when 
stimulated by surgery than by LPS and there is a suggestion of a response from more 
diverse populations of leucocytes such as eosinophils. 
Therefore although the surgical stimulus is relatively mild, a simple incision; and the 
chance of LPS contamination low there are still high numbers of leucocytes in the 
peritoneum.  The clinical question is whether these recruited cells can create the 
inflammatory conditions within the peritoneum that lead to peritonitis and is this of 
sufficient magnitude to cause multi-organ failure.  
 
Priming is the process by which cells of the immune system produce a heightened 
response following earlier low dose exposure to a stimulus (188).  This can also occur 
as a spatial effect such as the augmented response of inflammatory cells following 
adherence to endothelium (189). The priming of neutrophils by this adherence may 
trigger de-granulation and release of superoxides and/or lipid mediators and delay 
apoptosis (190).  The increase in the production of TNFα after consecutive doses of 
LPS is related to the site of injection with the intravenous route requiring a much 
lower dose than injections into tissue (191).  It has been found previously by our 
group that monocytes recruited to the lung capillaries by a sub-clinical dose of LPS 
did not produce a significant amount of TNFα, but were primed to respond vigorously 
to a subsequent dose of LPS even if that was also below the threshold for clinical 
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signs to develop (132).  Pre-treatment with LPS increased the numbers of Gr-1Hi 
monocytes and neutrophils marginating in the lung vasculature, and that when 
ventilated with high stretch the signs of lung injury were significantly increased (133).  
Both of these studies suggest that monocytes mobilise from both the circulating pool 
and bone marrow in response to an initial insult and are then primed within the 
pulmonary vasculature to become more inflammtory or cause more cell damage if 
challenged again.   
In tissues, macrophages are also available to be primed.  Alveolar macrophages 
exposed to LPS in-vivo had a greater resposne when subsequently challenged ex-vivo, 
than macrophages only exposed to saline initially (192).  Finally, in response to a 
spinal cord injury circulating CD14dimCD16+ monocytes are primed as they migrate 
into the cerebral spinal fluid to produce anti-inflammatory cytokines when activated 
by adhesion to cells of the chorid plexus (193). 
The priming of leucocytes and their response to repeated inflammatory challenges has 
been examined in several different scenarios.  The combination of insults used is 
varied and extensive but includes CLP and intra-tracheal LPS to study acute lung 
injury (194); sub-clinical iv LPS and iv zymosan (132);  pancreatitis and iv LPS 
(195); intra-tracheal LPS followed by intravenous LPS to examine lung permeability 
(196); subclinical intravenous doses of LPS and Platelet activating factor to examine 
lung injury (197).  The majority of these 2-hit models use insults that alone have a 
limited clinical or biochemical effect, together most result in profound changes. 
 
Aim 1: Describe the effect of a secondary local challenge with LPS after 
abdominal surgery on systemic (plasma) and local (peritoneal lavage) soluble 
TNF levels.  
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Aim 2: Investigate the inflammatory response of a secondary exposure to LPS 
in subpopulations of recruited and resident cells following abdominal surgery. 
 
It is well known in clinical practice that inflammatory insults that may appear 
innocuous can be have significant effects at organ sites distant from the origin of 
inflammation.  There are many examples including pancreatitis, trauma, 
cardiopulmonary bypass, burns and sepsis that can require multi-organ support.  The 
most common distant site to be affected is the lung.  There are several reasons for 
this; the entire cardiac output has to pass through the pulmonary vasculature so any 
circulating factors produced by the SIRS response will come into contact with the 
endothelium; leucocytes are known to marginate to the lung (132,133); the lung 
capillaries are very small, 2-2.5µm in diameter causing leucocytes to deform (they are 
normally 8µm in diameter) to pass through, providing significant endothelial contact 
and potential hold up (198). 
Peritonitis often leads to the development of an acute lung injury.  This association 
has been known for a long time (199), it is especially common following surgery for 
abdominal emergencies such as a perforated viscus (200).  Peritonitis has been 
exploited to investigate the soluble factors that trigger acute lung injury using many 
different animal models including mice (201), rats (202) and pigs (203). 
If the recruited monocytes are primed to produce a greater response when challenged 
again by LPS even at low dose this may reach the threshold at which systemic effects 
begin to appear.  The lung will be one of the first distant organ sites to be effected and 
is therefore reasonable to examine pulmonary tissue for the early changes of acute 
lung injury such as capillary leak and development of extravascular lung water. 
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Aim 3: Examine the effects on the lung of the recruitment of monocytes to the 
peritoneal cavity by surgery and subsequent ‘second hit’ by ip  LPS.  
 
Protocols 
“Two hit” protocol 
The surgical procedure has already been described in chapter 2.  C57BL/6 mice were 
operated on and allowed to recover.  They were kept in separate cages for the next 24 
hours and then received no injection or an intra-peritoneal injection of 20ng LPS or 
saline also as previously described.  One hour later they were sacrificed and peritoneal 
lavage fluid obtained.   
Peak recruitment of cells for intra-peritoneal LPS and surgery occurred at slightly 
different time points for the two-monocyte subsets but was significant at 24 hours for 
both. As both subsets were present in lavage samples at 24 hours this was chosen as 
the time point to introduce the second hit. The rationale for using 20ng LPS as a sub-
clinical none saturating dose of LPS was described in chapter 3 and therefore this was 
the dose used as the second hit. 
 
Assessment of inflammatory status 
To examine the effects of the 2-hit model on peritoneal inflammation, LPS challenge 
was performed either in vivo by ip injection of 20ng or ex-vivo following peritoneal 
lavage with LPS at a concentration of 20ng/ml. 
To determine the amount of soluble TNFα present in the peritoneal lavage fluid, cells 
were not incubated with the metalloprotease inhibitor BB94 (TACE inhibitor) 
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allowing shedding of TNFα from the cell surface.  They were also incubated with LPS 
for longer (4 hours), the supernatant collected and soluble TNFα measured by ELISA. 
To measure the amount of membrane bound TNFα,  BB94 was added to the 20ng 
dose of LPS or the control dose of saline to prevent TACE-mediated release of TNFα 
from the cell surface and thereby determine the total memTNFα production by 
individual cells in the 1 hour period.   
As described in chapter 2 using flow cytometry and antibodies directed against 
membrane bound TNFα the expression of this pro-inflammatory cytokine can be 
assessed on both monocyte subsets.   
 
Assessment of lung permeability 
Mice were divided into 2 groups, one underwent abdominal surgery as described in 
chapter 2.  The other group, the controls, had no surgical procedure.  24 hours later 
both groups received LPS and were allowed to recover for 2 hours.  
The mice from each group were sacrificed and underwent dye dilution experiments as 
described in chapter 2.  Briefly two albumin-conjugated dyes of linked to different 
wavelength flurophores were injected intravenously at separate time points.  The 
lungs were subsequently excised, homogenized and the supernatant measured for 
fluorescence.  By measuring the lung:blood ratio for each flurophore, an index of lung 







The effect of abdominal surgery on peritoneal TNFα levels following a secondary 
LPS challenge. 
The in-vivo animals exposed to a ‘primary hit’ surgery and a ‘secondary hit’ LPS 
were compared to those exposed to LPS alone or surgery alone. A trend towards an 
increase in the level of soluble TNFα detectable in the peritoneal lavage fluid was 




Figure 1. Soluble TNFα levels in peritoneal fluid an in-vivo 2-hit model. Mice were 
divided into three groups, one had surgery and was allowed to recover, one received 
LPS and was sacrificed 4 hours later and the final group had surgery and 24 hours 


















Surgery - + +
LPS + - +
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Despite being able to detect TNFα in the peritoneal cavity at 4 hours levels in the 
plasma were below the detection limits of the ELISA.  This result may not be 
surprising considering the low dose of LPS used and the reported short half life of 
TNF in blood of 18 minutes (204).  
 
Is the increase in soluble TNFα in the peritoneal cavity of animals exposed to 
surgery and LPS related to a second wave of migration of inflammatory cells? 
To discover whether there is any further recrutiment of inflammatory cells by the 
second LPS stimulation that might add to the response of the already recruited cells, 
three groups of mice were compared. 2 subjected to surgery, one of which received a 
secondary challenge with intra-peritoneal LPS and a third group receiving LPS only.  
LPS was injected 24 hours post-surgery and cells harvested by lavage 1 hour later.   
There was no additional recruitment of monocytes to the peritoneal cavity in either 
the control animals that underwent just surgery and subsequently received ip saline or 
the 2-hit animals (Gr-1Hi: Control 4.5±1.0x105; 2-hit 5.6±1.2x105 t-test p=0.48)(Gr-
1Lo: Control 11±2.7x105; 2-hit 8.4±2.4x105 t-test p=0.46).  The only cell line to 
appreciably increase after surgery and secondary LPS were the neutrophils (Surgery 
alone 7.8±1.3x105; LPS alone 3.2±1.0x105 2-hit 22±4.9x105 p=0.0009).  This 
additional recruitment suggests that a priming of the immune response to secondary 
‘infectious’ challenge as a result of aseptic abdominal surgery (Figure 2). 
As the neutrophil contribution to TNFα production is likely to be small (see below) 
the increase in soluble TNFα within peritoneal fluid following surgery and LPS can 





Figure 2.  The effect of abdominal surgery and a second hit of LPS on leucocyte 
migration into the peritoneal cavity.  The effect of ip LPS on peritoneal leucocyte 
numbers was determined at 24hours post abdominal surgery.  Lavage was performed 
1 hour after 20ng LPS was injected and total leucocyte subpopulation numbers 
determined by flow cytometry. n=7control and 10intervention. 
 
Expression of membrane bound TNFα on macrophages and monocytes recruited 
by surgery and subsequently exposed to LPS with BB94 in-vivo. 
The expression of memTNFα in the 2-hit animals was compared to animals exposed 
to LPS without surgery and animals that underwent surgery but were not exposed to 
LPS.  The secondary LPS challenge or control saline was performed in vivo with 
BB94 prior to cell harvest by peritoneal lavage after 1 hour.   Shown here in (Figure 
3) at 1 hour post LPS there are minimal Gr-1Hi monocytes present in the peritoneal 
cavity and therefore it was not considered possible to determine their response in non 
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The Gr-1Hi monocytes challenged in-vivo by LPS following surgery expressed high 
levels of membrane bound TNFα with those undergoing surgery only exhibiting 
negligible amounts in comparison (Surgery alone 4.6±1.1; Surgery + LPS 
156.6±56.02).  However it was not possible to assess a priming effect of surgery on 
the response to LPS because no Gr-1Hi monocyte were present in LPS only challenged 




Figure 3.  TNFα expression on Gr-1Hi monocytes in-vivo.  Mice underwent 
abdominal surgery and recovered.  At 24 hours they received either 20ng of LPS or 
0.9% saline and were sacrificed one hour later.  The MFI of membrane bound TNFα 













Figure 4.  In control mice challenged with LPS and sacrificed after 1 hour there are 
no resident Gr-1Hi monocytes (see highlighted area) 
 
The Gr-1Lo monocytes in the 2-hit animals demonstrated a similar, albeit slightly 
lower, TNFα response compared to the Gr-1Hi subset (Figure 5).  Unlike the case for 
the Gr-1Hi monocytes, the presence of a resident Gr-1Lo like phenotype in mice 
receiving LPS alone allowed some estimation of the effect of the prior surgery on LPS 
responsiveness.  Based on this premise, the effect of surgery on responsiveness 





Figure 5. TNF expression on Gr-1Lo monocytes in-vivo.  Mice underwent 
abdominal surgery and recovered.  At 24 hours they received either 20ng of LPS or 
0.9% saline and were sacrificed one hour later. A further group did not undergo 
surgery but received LPS (20ng) 1 hour prior to sacrifice.  The MFI of membrane 
bound TNFα on Gr-1Lo monocytes was measured. One-way ANOVA p=0.0004. 
*p<0.05 n=9control and 11intervention. 
 
Finally the expression of TNFα on the resident macrophages was assessed (Figure 6), 
again in the three groups of animals.  These cells responded to the surgical insult by 
expressing the most TNFα of all the leucocyte sub-populations studied although, the 
intensity of response in the recruited monocyte subsets was of a comparably high 
magnitude.  This direct comparison of resident cells provided the most clear cut 
evidence of priming of the inflammatory response within the peritoneal cavity due to 
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Figure 6.  TNFα expression on resident macrophages.  Mice underwent abdominal 
surgery and recovered.  At 24 hours they received either 20ng of LPS or 0.9% saline 
and were sacrificed one hour later. A further group did not undergo surgery but 
received LPS (20ng) 1 hour prior to sacrifice.  The MFI of membrane bound TNFα on 
resident macrophages was measured. One-way ANOVA p=0.02. *<0.05. n=5control 
and 9intervention. 
 
The expression of membrane bound TNFα on macrophages and monocytes 
recruited by surgery, harvested and then exposed ex-vivo to LPS. 
In order to rule out the possibility that the results observed in vitro were influenced by 
the selective recovery of cells due to the ‘macrophage disappearance reaction’ and to 
consider the effect of the in vivo environment on priming, stimulation experiments 








Surgery + - +
LPS - + +
*
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The Gr-1Hi monocytes expressed significantly more membrane bound TNFα 
following surgery and a ‘second hit’ of LPS than those cells exposed to surgery and 




Figure 7.  Expression of TNFα on Gr-1Hi monocytes after ex-vivo stimulation.  
Mice underwent abdominal surgery, at 24 hours they were sacrificed and peritoneal 
lavage fluid obtained.  The harvested cells were then exposed ex-vivo to either LPS or 
0.9% saline and the MFI of TNFα expressed on Gr-1Hi monocytes calculated by 1 
hour later. Mann Whitney U p=0.03. n=3control and 8intervention 
 
Although the Gr-1Lo cells demonstrated a similar trend towards higher expression of 
TNFα after LPS this did not reach significance (Surgery only group 38.6±21.4; LPS 











Figure 8.  Expression of TNFα on Gr-1Lo monocytes after ex-vivo stimulation.  
Mice underwent abdominal surgery, at 24 hours they were sacrificed and peritoneal 
lavage fluid obtained.  The harvested cells were then exposed ex-vivo to either LPS or 
0.9% saline.  A further group did not undergo surgery but lavage was performed and 
the cells exposed to 20ng LPS for 1 hour.  The MFI of TNFα on Gr-1Lo monocytes 
was measured.  One-way ANOVA p=0.13; n=3control and 8intervention. 
 
As in the in-vivo groups the resident macrophages had the highest expression of 
membrane bound TNFα (Surgery only group 35.7±9.5; LPS only group 10.4±7.1; 
Surgery + LPS 238±49.5)(Figure 9).  In conclusion, these ex-vivo experiments 
demonstrated a similar pattern to the challenges performed in vivo supporting their 
interpretation and suggesting that the intensity of responses was not dependent on 
cues from the in-vivo environment.  The consistency of the effect between the in-vivo 
and the ex-vivo experiments suggests that this was not related to selective cell 
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Figure 9. Expression of TNFα in macrophages after ex-vivo LPS stimulation.  Mice 
underwent abdominal surgery, at 24 hours they were sacrificed and peritoneal lavage 
fluid obtained.  The harvested cells were then exposed ex-vivo to either LPS or 0.9% 
saline.  A further group did not undergo surgery but lavage was performed and the 
cells exposed to 20ng LPS for 1 hour.  The MFI of TNFα on the resident macrophages 
was measured.  One-way ANOVA p=0.0001; *p<0.05; n=3control and 11intervention. 
  
Neutrophils did not express any TNFα in either the in-vivo or ex-vivo models. 
 
 
Is the insult of surgery and exposure to LPS sufficient to trigger SIRS and cause 
effects at distant organ sites. 
The in-vivo and ex-vivo data strongly suggest that macrophages and the cells that 
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simple surgical incision to increase their pro-inflammatory response to a subsequent 
challenge with LPS.   
Peritonitis is known to lead to multi-organ failure especially lung injury.  To 
investigate whether the migration and increased responsiveness of the monocytes in 
the peritoneal cavity was sufficient the 2-hit model was modified to include a test of 
lung permeability.   
Using the low-dose LPS (20ng) used in the previous trafficking and priming 
experiments the mice were completely asymptomatic.  Changes in lung permeability 
in mice who are well has little clinical significance. From the experiments performed 
in chapter 2 a 20µg intra-peritoneal dose of LPS is known to make mice symptomatic 
with piloerection and reduced movement, therefore this dose was used as the 




Figure 10.  Dye dilution calculation of lung permeability.  Mice were divided into 2 
groups, the first underwent surgery, recovered and then received a 20µg dose of ip 
LPS.  The other received LPS alone.  A permeability index was constructed using a 2-










There was a trend towards an increase in lung permeability in the group primed by 
surgery prior to LPS exposure although this did not reach significance. 
This trend is important, as it is suggestive that monocytes and macrophages are 
primed by minor surgery to vigorously respond to LPS leading to systemic as well as 
local effects.  
 
Discussion 
Macrophages, as sentinel cells, are present in tissue to activate and respond to 
invaders.  The fact that these cells have the highest expression of TNFα may represent 
this early response. Gr-1Lo monocytes, when exposed to LPS demonstrate a much 
higher expression of TNFα than cells recruited by LPS or surgery alone.  This 
provides strong evidence of a priming effect on the monocytes recruited, either via an 
interaction with the endothelial/peritoneal lining or via an internal priming mechanism 
within the monocyte.   It is difficult to prove a priming effect by minor surgery for the 
Gr-1Hi monocyte subset, as there are almost no cells of this phenotype in the 
peritoneal cavity one hour after LPS.  Priming remains likely given the lack of an 
effect on the resident macrophages or Gr-1Lo monocytes, an alternative comparison 
would be with the circulating blood Gr-1Hi monocytes.  This has important clinical 
connotations, the threshold for development of the systemic inflammatory response 
syndrome is lowered by minor surgery to the extent that at a local level within the 
peritoneal cavity doses of LPS (20ng) that would otherwise not trigger an 
inflammatory response, do so.  There is also a systemic effect with pathophysiological 




The mechanism by which local inflammation within the peritoneal cavity leads to a 
systemic effect is related to not only the spill over of PAMPs and DAMPs but also the 
migration of soluble mediators produced by inflammatory cells into the circulation 
(183).  Soluble TNFα levels in the peritoneal lavage fluid at 4 hours are higher but not 
statistical so in the 2-hit group, this is of interest as the levels of memTNFα are much 
higher in the 2-hit model.  There are several reasons for this, the soluble levels are a 
snapshot at 4 hours, it is likely that more TNFα is synthesized and moved to the cell 
membrane. The shedding of TNF from the cell membrane occurs under the influence 
of TACE and this post-translational effect appears to be the rate-limiting step in 
soluble TNFα release.  If TNFα is not cleaved it is rapidly recycled into the cell (205). 
Binding to soluble TNF receptors in the peritoneal lavage fluid may also neutralize 
the soluble TNFα; these receptors are also cleaved by the action of TACE (59) The 
presence of LPS may directly effect the amount and activity of TACE.  Several 
authors have found that TACE mRNA is upregulated by LPS stimulation (206-208) 
although others who have found a decline in both TACE fluorescence and activity 
after LPS exposure dispute this (209). Finally, soluble TNFα is rapidly cleared from 
plasma with a half-life in LPS challenged mice of 6-7 mins (210).  It initially re-
distributes to areas of high blood flow including the liver, kidney and GI tract.  Once 
bound rapid degradation occurs, so that the elimination half-life is 8-10 minutes.  
These mechanisms of TNF redistribution may have reduced the soluble levels 
especially in the 2-hit groups with the more activated cells. 
 
The numbers of monocytes do not increase with further exposure to a second sub-
clinical dose of LPS although there is a second recruitment of neutrophils.  Wilson et 
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al demonstrated that in mice pre-treated with LPS and then ventilated with high 
stretch there is a second recruitment of monocytes to the pulmonary vasculature after 
the second stimulus (133). This inconsistency with our data may be related to the 
initial stimulus trapping monocytes in the pulmonary circulation that are then 
available to migrate following localized damage from high stretch ventilation.  
Interestingly there are approximately 4 times as many Gr-1Lo monocytes found in the 
lavage fluid as in the lung, this may be due to the longer time period of our 
experiments with more in-situ maturation from Gr-1Hi cells.   
Neutrophils were recruited early in response to surgery peaking at around 2 hours, un-
expectantly a second wave responded to the secondary stimulus of LPS.  These were 
significantly raised even at one hour post-injection suggestive that surgery has another 
form of priming affect, in terms of neutrophil numbers.  Primed neutrophils have been 
shown to over expresses adhesion molecules on the promoting attachment to 
endothelium and therefore migrate to areas of inflammation much quicker (211) 
 
The effect of surgery on the immune system has been extensively studied both in 
animals and humans. Caecal ligation and puncture (CLP) has been used extensively to 
model sepsis in animals including mice.  It has been argued that CLP or a similar 
procedure colon ascendens stent procedure (CASP) most accurately models the 
formation of peritonitis and sepsis in humans (138). The ligation introduces an 
element of necrotic tissue, the reason 90% of animals die (212) and the size and 
number of punctures allows control of the speed of the septic insult.  However there 
are variables related to the size of incision, the size of the needle, the extent of 
necrosis and the skill of the operator.  Our two-hit model demonstrates that the 
surgery itself, in fact simply the incision, has a priming effect on monocytes that 
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increases the expression of TNFα and may effect the scale of subsequent pro-
inflammatory responses.  
As well as CLP there have been other surgical models used in the investigation of 
trauma (213), cancer (214)and inflammation (194).  Many of these examine the 
effects either in tissue, such as the lung or systemically in blood.  There are a few 
studies that looked specifically at the effect of the trauma of surgery on cell 
recruitment and its effects.   Van den Toll et al performed an incision and gut 
manipulation in rats and collected peritoneal lavage fluid.   On inoculation of this 
fluid into rats, the cellular component was responsible for an increase in tumor load 
(214).  This is the basis of the argument to reduce surgical trauma by utilising more 
laparoscopic techniques (215,216).  This has been supported by trials in rats 
comparing laparoscopic surgery to open surgery; significantly more TNFα is 
produced by peritoneal lavage cells after open surgery than after laparoscopic surgery 
(217).  These examples support our findings that the amount of memTNFα expressed 
in response to low-dose LPS is massively increased if preceded by surgery, even if the 
surgical insult is minor. 
There have been many two-hit models that have investigated the mechanisms behind 
the development of acute lung injury some of which have used peritoneal 
inflammation as the primary insult (194,218,219).  Lung permeability is increased 
when mice are primed with intra-tracheal LPS 18 hours before a second intra-tracheal 
dose (218).  A reduction in cardiac output of 40% by haemorrhage primes rabbits to 
increase their lung permeability to a similar extent as seen in our experiment, with 
further exposure to intravenous LPS (219).  Of note, it is the development of sepsis 
after priming that triggers the increase in lung permeability this was demonstrated by 
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Czermak who compared CLP animals with sham laparotomy animals as the initial 
insult and showed evidence of increased permeability with subsequent LPS only in 
the CLP primed group (194).  The mechanism of this systemic activation is likely to 
be related to spill over of not just LPS (154) but also DAMPs released by surgical 
trauma (146) and pro-inflammatory cytokines produced by the recruited cells (210). 
In conclusion, there is evidence that a minor surgical incision is able to recruit 
leucocytes and following a ‘second hit’ of LPS activate both those sub-populations 
and the resident populations to significantly increase the expression of pro-
inflammatory cytokines and their release as soluble mediators. Priming of leucocytes 
and the development of lung injury has been previously shown to occur but not with 
the relatively minor insult of a surgical incision and not with the ‘second hit’ confined 


































The comparison of intra-peritoneal LPS with a surgical incision show that sub-
populations of circulating leucocytes are recruited to the peritoneum in a broadly 
similar pattern.  The comparison of cell counts between the groups is tricky as 
choosing a dose of LPS equivalent to the surgical incision is not possible, however the 
size of the recruitment with surgery remains surprising.  Previously it was felt that 
PAMPs were the predominant recruiter of leucocytes when compared to DAMPs with 
faster mobilisation of neutrophils in greater number from bone marrow (220,221). 
This may be related to the location of the stimulus within the peritoneal cavity, 
capturing both DAMPs and migrated cells leading to greater cell recruitment.  Zhang 
et al (38) have suggested a mechanism for lymphocyte recruitment following tissue 
damage.  They used both rat and mouse models of injury detecting significant 
amounts of mitochondrial DNA following injury when compared to sham controls.  
They studied the activation of neutrophils at 2 hours via TLR-9, with a downstream 
effect of activating the p38 MAP-K system.  This activation of the p38 MAP-K 
pathway is similar to that described by O’Dea et al (134) in Gr-1Hi monocytes 
following intravenous LPS.  This is likely to represent just one of many DAMPs and 
downstream pathways activated by tissue injury. This pathway is likely to increase the 
adhesion of Gr-1Hi monocytes to the mesenteric endothelium leading to more 
margination/migration and trigger intra-cellular components of the p38 MAP kinase 
system that are already known to lead to greater expression of pro-inflammatory 
mediators such as iNOS and TNFα (222,223).  
 
In a rat model of traumatic brain injury there is an increase at 6 hours in the levels of 
CCL2 mRNA within the CSF and this leads to a widening of tight junctions and 
migration of monocytes into the CSF by 24hours (224). CSF monocytosis is known to 
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trigger an inflammatory cascade, worsen oedema and prevent neuronal recovery (225).  
The inflammation following spinal cord injury appears to be mediated by the early 
infiltration of both neutrophils and monocytes and, in a murine model, blocking 
adhesion and subsequent migration improves neurological recovery (226).  Seitz 
(227), using a rat model of chest trauma, showed that significant numbers of pro-
inflammatory monocytes (analogous to Gr-1Hi cells in mice) were recruited to the lung 
in areas releasing significant amounts of CCL-2.  These three studies demonstrate that 
levels of CCL2 are increased in areas of tissue injury and this has an attractant effect 
on circulating monocytes.  They suggest that the recruitment of leucocytes, the 
upgrading of pro-inflammatory cytokines and the change in clinical symptoms occur 
in many tissues.  However the peritoneal cavity is unique, it provides an environment 
for co-culture of DAMP’s or PAMP’s with leucocytes, promoting their activation 
whilst reducing the opportunity for containment.  Translocation or spillover from 
areas of injury of commensal bacteria makes infection a real possibility and the data 
suggests that SIRS in this situation would be highly likely.  To further investigate 
these effects an analysis of the recruitment of pro-inflammatory cells to the liver and 
gut mesentery would be useful.  The liver especially has a very good blood supply 
from the bowel via the portal venous system.  In the context of liver surgery or injury, 
priming may occur in the resident macrophages (Kuppffer cells) that make a systemic 
response much more likely following a secondary infective challenge (228).  Whether 
this is of the same magnitude as that seen in the peritoneal cavity would be interesting.  
Further animal work could also be directed towards exploring how the 
margination/migration kinetics of monocytes could be modified and what knock on 
effects this would have in terms of survival from the initial insult. 
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The differential functions of the monocyte subsets and the effect of priming have been 
seen in both animal models and real patients.  In a mouse model of Crohns disease the 
dominant monocytes in the lamina propria are the Gr-1Hi monocytes, they upregulate 
TLR-2 and having migrated into the gut wall become activated by bacterial 
components and differentiate into efficient antigen presenting cells priming T cells 
(229).  In humans with Crohn’s disease, monocytes are felt to be the most important 
leucocyte involved in the pathogenesis of gut wall inflammation.  There is some 
evidence that monocytes from patients with Crohn’s are primed, by an as yet 
unknown factor, to produce significantly higher levels of superoxide when further 
challenged by LPS (230). More recently monocytes from Crohn’s patients and 
assumed to be primed by chronic inflammation produced much more IL-1β, CCL-2 
and CCL-5 than those from healthy controls (231). 
The difficulty of repeating this study in humans is the lack of control of the 
heterogenous population undergoing surgery.  It is not possible to examine the 
leucocyte response to select parts of the surgical technique but intra-abdominal drains 
could be utilised to sample peritoneal fluid over time and describe the kinetics.  This 
access to the peritoneal cavity is also available in longer-term liver disease patients 
requiring ascitic drainage or those receiving peritoneal dialysis. It may be wise to first 
describe the in-situ responses of mice to whole bacteria rather than a single PAMP 
such as LPS and compare and contrast both the recruitment and activation of the cells 
involved.  There is some interdependence between the immune system and the 
neurohumoral system and this model allows further exploration of this especially the 




Should a similar effect be evident in human monocytes it suggests that the tissue 
damage caused by surgery or trauma can prime the innate immune system to 
vigorously respond to subsequent challenges?  If the threshold of SIRS is significantly 
lowered by prior surgery then it provides further argument that by reducing tissue 
damage with minimally invasive techniques the impact of subsequent complications 
could be lessened.   
However if open surgery is required are there any useful medical interventions that 
could reverse this process of recruitment and activation.  Certainly the history of 
immunomodulatory therapies in the context of sepsis and intensive care is one of 
failure and it seems counter-intuitive that patients with healing wounds after surgery 
would benefit from immunosuppression.   There are arrays of different molecules that 
can trigger several pattern recognition receptors acting in many distinct downstream 
pathways.  The redundancy in the system is so great that an intervention at one 
specific point can be simply bypassed, with inflammation continuing unchecked.  
Perhaps future immune interventions will be designed based on individuals genetic 
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